المؤلفون: A. M. Lila, L. I. Alekseeva, E. A. Taskina, N. G. Kashevarova, E. P. Sharapova, E. A. Strebkova, N. M. Savushkina, A. R. Khalmetova, V. A. Nesterenko, A. S. Avdeeva, E. Yu. Samarkina, M. E. Diatroptov, O. G. Alekseeva, А. М. Лила, Л. И. Алексеева, Е. А. Таскина, Н. Г. Кашеварова, Е. П. Шарапова, Е. А. Стребкова, Н. М. Савушкина, А. Р. Хальметова, В. А. Нестеренко, А. С. Авдеева, Е. Ю. Самаркина, М. Е. Диатроптов, О. Г. Алексеева

المساهمون: The article was prepared within the framework of research work, government task № 1021051403074-2. The investigation has not been sponsored, Статья подготовлена в рамках научно-исследовательской работы, государственное задание № 1021051403074-2. Исследование не имело спонсорской поддержки

المصدر: Modern Rheumatology Journal; Том 18, № 3 (2024); 14-24 ; Современная ревматология; Том 18, № 3 (2024); 14-24 ; 2310-158X ; 1996-7012

مصطلحات موضوعية: олокизумаб, inflammatory phenotype, interleukin 6, olokizumab, воспалительный фенотип, интерлейкин 6

وصف الملف: application/pdf

Relation: https://mrj.ima-press.net/mrj/article/view/1584/1467; GBD 2021 Osteoarthritis Collaborators. Global, regional, and national burden of osteoarthritis, 1990-2020 and projections to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Rheumatol. 2023 Aug 21;5(9):e508-e522. doi:10.1016/S2665-9913(23)00163-7.; Muthu S. Osteoarthritis, an old wine in a new bottle! World J Orthop. 2023 Jan 18;14(1): 1-5. doi:10.5312/wjo.v14.i1.1.; Мазуров ВИ, Лила АМ, Алексеева ЛИ и др. Мультиморбидность при остеоартрите и плейотропные эффекты симптоматических средств замедленного действия. Резолюция международного мультидисциплинарного совета экспертов. Современная ревматология. 2023;17(5):123-131. doi:10.14412/1996-7012-2023-5-123-131.; Sanchez-Lopez E, Coras R, Torres A, et al. Synovial inflammation in osteoarthritis progression. Nat Rev Rheumatol. 2022 May;18(5): 258-275. doi:10.1038/s41584-022-00749-9.; Herrero-Beaumont G, Roman-Blas JA, Bruyere O, et al. Clinical settings in knee osteoarthritis: Pathophysiology guides treatment. Maturitas 2017 Feb:96:54-57. doi:10.1016/j.maturitas.2016.11.013.; Mathiessen A, Conaghan PG. Synovitis in osteoarthritis: current understanding with therapeutic implications. Arthritis Res Ther. 2017 Feb 2;19(1):18. doi:10.1186/s13075-017-1229-9.; Calvet J, Berenguer-Llergo A, Orellana C, et al. Specific-cytokine associations with outcomes in knee osteoarthritis subgroups: breaking down disease heterogeneity with phenotyping. Arthritis Res Ther. 2024 Jan 11;26(1):19. doi:10.1186/s13075-023-03244-y.; Dell'Isola A, Allan R, Smith SL, et al. Identification of clinical phenotypes in knee osteoarthritis : a systematic review of the literature. BMC Musculoskelet Disord. 2016 Oct 12;17(1):425. doi:10.1186/s12891-016-1286-2.; Henrotin Y. Osteoarthritis in year 2021: biochemical markers. Osteoarthritis Cartilage. 2022 Feb;30(2):237-248. doi:10.1016/j.joca.2021.11.001. Epub 2021 Nov 16.; Angelini F, Widera P, Mobasheri A, et al. Osteoarthritis endotype discovery via clustering of biochemical marker data. Ann Rheum Dis. 2022 May;81(5):666-675. doi:10.1136/annrheumdis-2021-221763.; Li S, Cao P, Chen T, Ding C. Latest insights in disease-modifying osteoarthritis drugs development. Ther Adv Musculoskelet Dis. 2023 May 13:15:1759720X231169839. doi:10.1177/1759720X231169839.; Vrouwe JPM, Burggraaf J, Kloppenburg M, Stuurman FE. Challenges and opportunities of pharmacological interventions for osteoarthritis: A review of current clinical trials and developments. Osteoarthr Cartil Open. 2021 Sep 8;3(4):100212. doi:10.1016/j.ocarto.2021.100212.; Лапкина НА, Баранов АА, Левшин НЮ и др. Динамика клинических проявлений и концентрации цитокинов у больных ревматоидным артритом на фоне терапии олокизумабом. Научно-практическая ревматология. 2023;61(4):475-484.; Akeson G, Malemud CJ. A Role for Soluble IL-6 Receptor in Osteoarthritis. J Funct Morphol Kinesiol. 2017;2(3):27. doi:10.3390/jfmk2030027. Epub 2017 Aug 2.; Beekhuizen M, Gierman LM, van Spil WE, et al. An explorative study comparing levels of soluble mediators in control and osteoarthritic synovial fluid. Osteoarthritis Cartilage. 2013 Jul;21(7):918-22. doi:10.1016/j.joca.2013.04.002. Epub 2013 Apr 15.; Sohn DH, Sokolove J, Sharpe O, et al. Plasma proteins present in osteoarthritic synovial fluid can stimulate cytokine production via toll-like receptor 4. Arthritis Res Ther. 2012 Jan 8;14(1):R7. doi:10.1186/ar3555.; Wang ZW, Chen L, Hao XR, et al. Elevated levels of interleukin-1beta, interleukin-6, tumor necrosis factoralpha and vascular endothelial growth factor in patients with knee articular cartilage injury. World J Clin Cases. 2019 Jun 6;7(11):1262-1269. doi:10.12998/wjcc.v7.i11.1262.; Livshits G, Zhai G, Hart DJ et al. Interleukin-6 is a significant predictor of radiographic knee osteoarthritis: the Chingford Study. Arthritis Rheum 2009;60 (7):2037–45. doi:10.1002/art.24598.; Stannus O, Jones G, Cicuttini F, et al. Circulating levels of IL-6 and TNF-alpha are associated with knee radiographic osteoarthritis and knee cartilage loss in older adults. Osteoarthritis Cartilage. 2010 Nov;18(11):1441-7. doi:10.1016/j.joca.2010.08.016. Epub 2010 Sep 16.; Goekoop RJ, Kloppenburg M, Kroon HM, et al. Low innate production of interleukin-1beta and interleukin-6 is associated with the absence of osteoarthritis in old age. Osteoarthritis Cartilage. 2010 Jul;18(7):942-7. doi:10.1016/j.joca.2010.03.016. Epub 2010 Apr 22.; Tsuchida AI, Beekhuizen M, Rutgers M, et al. Interleukin-6 is elevated in synovial fluid of patients with focal cartilage defects and stimulates cartilage matrix production in an in vitro regeneration model. Arthritis Res Ther. 2012 Dec 3;14(6):R262. doi:10.1186/ar4107.; Tsuchida AI, Beekhuizen M, `t Hart MC, et al. Cytokine profiles in the joint depend on pathology, but are different between synovial fluid, cartilage tissue and cultured chondrocytes. Arthritis Res Ther. 2014 Sep 26;16(5):441. doi:10.1186/s13075-014-0441-0.; Guerne PA, Zuraw BL, Vaughan JH, et al. Synovium as a source of interleukin 6 in vitro. Contribution to local and systemic manifestations of arthritis. J Clin Invest. 1989 Feb;83(2): 585-92. doi:10.1172/JCI113921.; Bondeson J, Wainwright SD, Lauder S, et al. The role of synovial macrophages and macrophage-produced cytokines in driving aggrecanases, matrix metalloproteinases, and other destructive and inflammatory responses in osteoarthritis. Arthritis Res Ther. 2006;8(6): R187. doi:10.1186/ar2099.; Nguyen HN, Noss EH, Mizoguchi F, et al. Autocrine loop involving IL-6 family member LIF, LIF receptor, and STAT4 drives sustained fibroblast production of inflammatory mediators. Immunity. 2017 Feb 21; 46(2):220-232. doi:10.1016/j.immuni.2017.01.004.; Wiegertjes R, van de Loo FAJ, Blaney Davidson EN. A roadmap to target interleukin-6 in osteoarthritis. Rheumatology (Oxford). 2020 Oct 1;59(10):2681-2694. doi:10.1093/rheumatology/keaa248.; Distel E, Cadoudal T, Durant S, et al. The infrapatellar fat pad in knee osteoarthritis: an important source of interleukin-6 and its soluble receptor. Arthritis Rheum. 2009 Nov; 60(11):3374-7. doi:10.1002/art.24881.; Pearson MJ, Herndler-Brandstetter D, Tariq MA, et al. IL-6 secretion in osteoarthritis patients is mediated by chondrocyte-synovial fibroblast cross-talk and is enhanced by obesity. Sci Rep. 2017 Jun 14;7(1):3451. doi:10.1038/s41598-017-03759-w.; Richette P, Latourte A, Sellam J, et al. Efficacy of tocilizumab in patients with hand osteoarthritis: double blind, randomised, placebo-controlled, multicentre trial. Ann Rheum Dis. 2021 Mar;80(3):349-355. doi:10.1136/annrheumdis-2020-218547.; Sanchez Huerta JM, Galvez-Romero J, Lopez-Rodriguez W, Lopez A. UTILITY OF Tocilizumab in clinical manifestations of erosive osteoarthrosis of hands regional hospital issste puebla, Mεxico. Ann Rheum Dis. 2017; 76(Suppl 2):974. doi:10.1136/annrheumdis-2017-eular.6483.; Kretsos K, Golor G, Jullion A, et al. Safety and pharmacokinetics of olokizumab, an anti-IL-6 monoclonal antibody, administered to healthy male volunteers: A randomized phase I study. Clin Pharmacol Drug Dev. 2014 Sep;3(5):388-95. doi:10.1002/cpdd.121. Epub 2014 May 26.; https://mrj.ima-press.net/mrj/article/view/1584

الاتاحة: https://mrj.ima-press.net/mrj/article/view/1584
https://doi.org/10.14412/1996-7012-2024-3-14-24

المؤلفون: N. G. Kashevarova, E. A. Taskina, E. A. Strebkova, E. P. Sharapova, N. M. Savushkina, T. A. Korotkova, L. I. Alekseeva, A. M. Lila, Н. Г. Кашеварова, Е. А. Таскина, Е. А. Стребкова, Е. П. Шарапова, Н. М. Савушкина, Т. А. Короткова, Л. И. Алексеева, А. М. Лила

المصدر: Modern Rheumatology Journal; Том 17, № 3 (2023); 51-59 ; Современная ревматология; Том 17, № 3 (2023); 51-59 ; 2310-158X ; 1996-7012

مصطلحات موضوعية: безопасность, local forms of non-steroidal anti-inflammatory drugs, tenoxicam, Artoxan gel, efficiency, safety, локальные формы нестероидных противовоспалительных препаратов, теноксикам, Артоксан гель, эффективность

وصف الملف: application/pdf

Relation: https://mrj.ima-press.net/mrj/article/view/1431/1361; Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2019 (GBD 2019) results. 2020. http://ghdx.healthdata.org/gbdresults-tool; Hunter DJ, March L, Chew M. Osteoarthritis in 2020 and beyond: a Lancet Commission. Lancet. 2020 Nov 28; 396 (10264):1711-2. doi:10.1016/S0140-6736 (20)32230-3.; Балабанова РМ, Дубинина ТВ. Динамика пятилетней заболеваемости болезнями костно-мышечной системы и их распространенности среди взрослого населения России за 2013–2017 гг. Современная ревматология. 2019;13(4):11-7. doi:10.14412/1996-7012-2019-4-11-17.; Галушко ЕА, Большакова ТВ, Виноградова ИБ и др. Структура ревматических заболеваний среди взрослого населения России по данным эпидемиологического исследования (предварительные результаты). Научно-практическая ревматология. 2009;(1):11-7.; Constantino de Campos G, Mundi R, Whittington C, et al. Osteoarthritis, mobilityrelated comorbidities and mortality: An overview of meta-analyses. Ther Adv Musculoskelet Dis. 2020 Dec 25;12:1759720X20981219. doi:10.1177/1759720X20981219. eCollection 2020.; Лила АМ, Алексеева ЛИ, Таскина ЕА. Современные подходы к терапии остеоартрита с учетом обновленных международных рекомендаций. Русский медицинский журнал. Медицинское обозрение. 2019;11-2:48-52.; Лила АМ, Ткачева ОН, Яхно НН и др. Комплексный подход к выбору терапии у пациентов с остеоартритом при первичном обращении к врачу. Консенсус экспертов (обзор литературы и резолюция). Современная ревматология. 2021; 15(3):111-6. doi:10.14412/1996-7012-2021-3-111-116; Лила АМ, Алексеева ЛИ, Таскина ЕА, Кашеварова НГ. Современный алгоритм лечения остеоартрита. Терапия. 2022; 8(2):65-76.; Leyland KM, Gates LS, Sanchez-Santos MT, et al. Knee osteoarthritis and time-to all-cause mortality in six community-based cohorts: an international meta-analysis of individual participant-level data. PCCOA Steering Committee. Aging Clin Exp Res. 2021 Mar;33(3):529-45. doi:10.1007/s40520-020-01762-2.; Таскина ЕА, Кашеварова НГ, Алексеева ЛИ. Место нестероидных противовоспалительных препаратов в современных рекомендациях по остеоартриту. Современная ревматология. 2020;14(2):123-30. doi:10.14412/1996-7012-2020-2-123-130.; Fayet M, Hagen M. Pain characteristics and biomarkers in treatment approaches for osteoarthritis pain. Pain Manag. 2021 Jan; 11(1):59-73. doi:10.2217/pmt-2020-0055. Epub 2020 Oct 30.; Bannuru RR, Osani MC, Vaysbrot EE, et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage. 2019 Nov;27(11):1578-89. doi:10.1016/j.joca.2019.06.011.; Bruyere O, Cooper C, Pelletier JP, et al. An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: a report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Semin Arthritis Rheum. 2014 Dec;44(3):253-63. doi:10.1016/j.semarthrit.2014.05.014. Epub 2014 May 14.; Каратеев АЕ, Насонов ЕЛ, Ивашкин ВТ и др. Рациональное использование нестероидных противовоспалительных препаратов. Клинические рекомендации. Научно-практическая ревматология. 2018; 56(Прил. 1):1-29. doi:10.14412/1995-4484-2018-1-29; Wolff DG, Christophersen C, Brown SM, Mulcahey MK. Topical nonsteroidal anti-inflammatory drugs in the treatment of knee osteoarthritis: A systematic review and metaanalysis. Phys Sportsmed. 2021 Nov;49(4):381-91. doi:10.1080/00913847.2021.1886573. Epub 2021 Mar 4.; McAlindon TE, Bannuru RR, Sullivan MC, et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis Cartilage. 2014 Mar;22(3):363-88. doi:10.1016/j.joca.2014.01.003. Epub 2014 Jan 24.; NICE. Osteoarthritis in over 16s: diagnosis and management NICE guideline Published: 19 October 2022. www.nice.org.uk/guidance/ng226; Hochberg MC, Altman RD, April KT, et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken). 2012 Apr;64(4): 465-74. doi:10.1002/acr.21596.; Jordan KM, Arden NK, Doherty M, et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis. 2003 Dec; 62(12):1145-55. doi:10.1136/ard.2003.011742.; Persson MSM, Stocks J, Walsh DA, et al. The relative efficacy of topical non-steroidal anti-inflammatory drugs and capsaicin in osteoarthritis: a network meta-analysis of randomised controlled trials. Osteoarthritis Cartilage. 2018; Dec;26(12):1575-82. doi:10.1016/j.joca.2018.08.008.; Kai S, Kondo E, Kawaguchi Y, et al. Flurbiprofen concentration in soft tissues is higher after topical application than after oral administration. Br J Clin Pharmacol. 2013 Mar; 75(3):799-804. doi:10.1111/j.1365-2125.2012.04394.x.; Mazieres B. Topical ketoprofen patch. Drugs R D. 2005;6(6):337-44. doi:10.2165/00126839-200506060-00003.; Taburet AM, Singlas E, Glass RC, et al. Pharmacokinetic comparison of oral and local action transcutaneous flurbiprofen in healthy volunteers. J Clin Pharm Ther. 1995 Apr; 20(2):101-7. doi:10.1111/j.1365-2710.1995.tb00636.x.; Hagen M, Baker M. Skin penetration and tissue permeation after topical administration of diclofenac. Curr Med Res Opin. 2017 Sep; 33(9):1623-34. doi:10.1080/03007995.2017.1352497. Epub 2017 Jul 18.; Kienzler JL, Gold M, Nollevaux F. Systemic bioavailability of topical diclofenac sodium gel 1% versus oral diclofenac sodium in healthy volunteers. J Clin Pharmacol. 2010 Jan;50(1):50-61. doi:10.1177/009127000 9336234. Epub 2009 Oct 19.; Honvo G, Leclercq V, Geerinck A, et al. Safety of Topical Non-steroidal Anti-Inflammatory Drugs in Osteoarthritis: Outcomes of a Systematic Review and Meta-Analysis. Drugs Aging. 2019 Apr;36(Suppl 1):45-64. doi:10.1007/s40266-019-00661-0.; Figueras A, Capellа D, Castel JM, Laorte JR. Spontaneous reporting of adverse drug reactions to non-steroidal antiinflammatory drugs. A report from the Spanish System of Pharmacovigilance, including an early analysis of topical and enteric-coated formulations. Eur J Clin Pharmacol. 1994;47(4):297-303. doi:10.1007/BF00191158.; Barkin RL. Topical Nonsteroidal AntiInflammatory Drugs: The Importance of Drug, Delivery, and Therapeutic Outcome. Am J Ther. 2015 Sep-Oct;22(5):388-407. doi:10.1097/MJT.0b013e3182459abd.; Evans JM, McMahon AD, McGilchrist MM, et al. Topical non-steroidal anti-inflammatory drugs and admission to hospital for upper gastrointestinal bleeding and perforation: a record linkage case-control study. BMJ. 1995 Jul 1;311(6996):22-6. doi:10.1136/bmj.311.6996.22.; Evans JM, McGregor E, McMahon AD, et al. Non-steroidal anti-inflammatory drugs and hospitalization for acute renal failure. QJM. 1995 Aug;88(8):551-7.; Shi C, Ye Z, Shao Z. Multidisciplinary Guidelines for the Rational Use of Topical Non-Steroidal Anti-Inflammatory Drugs for Musculoskeletal Pain. J Clin Med. 2023 Feb 15; 12(4):1544. doi:10.3390/jcm12041544.; Каратеев АЕ. Теноксикам. Клиническая фармакология и терапия. 2017;26(5): 44-50.; Vignon E, Mathieu P, Louisot P, Richard M. In vitro effect of nonsteroidal antiinflammatory drugs on proteoglycanase and collagenase activity in human osteoarthritic cartilage. Arthritis Rheum. 1991 Oct;34(10):1332-5. doi:10.1002/art.1780341021.; Баринов АН, Леонтьева МС, Телышева ЮБ и др. Современные подходы к диагностике и лечению первичной скелетномышечной ноцицептивной боли. Медицинский алфавит. 2023;(2):12-8.; https://mrj.ima-press.net/mrj/article/view/1431

الاتاحة: https://mrj.ima-press.net/mrj/article/view/1431
https://doi.org/10.14412/1996-7012-2023-3-51-59

المؤلفون: E. P. Sharapova, E. A. Taskina, N. G. Kashevarova, L. I. Alekseeva, A. M. Lila, Е. П. Шарапова, Е. А. Таскина, Н. Г. Кашеварова, Л. И. Алексеева, А. М. Лила

المساهمون: The investigation has been conducted within scientific topic «Development of methods of complex therapy for diseases of the musculoskeletal system» (№AAAA-Ф19-119021190150-6). Publication of this article has been supported by Sotex PharmFirma., Исследование выполнено в рамках научной темы «Разработка методов комплексной терапии заболеваний костно-мышечной системы» (№ НИОКТР АААА-Ф19-119021190150-6). Статья опубликована при поддержке компании ЗАО «ФармФирма «Сотекс».

المصدر: Modern Rheumatology Journal; Том 15, № 4 (2021); 120-125 ; Современная ревматология; Том 15, № 4 (2021); 120-125 ; 2310-158X ; 1996-7012

مصطلحات موضوعية: нежелательные явления, chondroitin sulfate, Chondroguard, efficiency, safety, adverse events, хондроитина сульфат, Хондрогард ®, эффективность, безопасность

وصف الملف: application/pdf

Relation: https://mrj.ima-press.net/mrj/article/view/1181/1138; Arden N, Nevit MC. Osteoarthritis: Epidemiology. Best Pract Res Clin Rheumatol. 2006 Feb;20(1):3-25. doi:10.1016/j.berh.2005.09.007; Галушко ЕА, Большакова ТЮ, Виноградова ИБ и др. Структура ревматических заболеваний среди взрослого населения России по данным эпидемиологического исследования (предварительные результаты). Научно-практическая ревматология. 2009;47(1):11-7.; Лила АМ, Лила ВА. Социальная значимость и экономические последствия ревматических заболеваний. Гигиена и санитария. 2017;96(4):387-92.; Sangha O. Epidemiology of rheumatic disease. Rheumatology (Oxford). 2000 Dec;39 Suppl 2:3-12. doi:10.1093/rheumatology/39.suppl_2.3.; Laurent TC, Laurent UB, Fraser JR. The structure and function of hyaluronan: An overview. Immunol Cell Biol. 1996 Apr;74(2): A1-7. doi:10.1038/icb.1996.32.; Стребкова ЕА, Соловьева ИВ, Шарапова ЕП и др. Оценка эффективности медикаментозной и немедикаментозной терапии ожирения у больных остеоартрозом коленных суставов. Тезисы VI Съезда ревматологов России. Москва; 2013. С. 152-3.; He Y, Li Z, Alexander PG, et al. Pathogenesis of Osteoarthritis: Risk Factors, Regulatory Pathways in Chondrocytes, and Experimental Models. Biology (Basel). 2020; 9(8):194. doi:10.3390/biology9080194; Ward PD, Thibeault SL, Gray SD. Hyaluronic acid: its role in voce. J Voice. 2002 Sep;16(3):303-9. doi:10.1016/s0892-1997(02)00101-7; Алексеева ЛИ, Таскина ЕА, Кашеварова НГ. Остеоартрит: эпидемиология, классификация, факторы риска и прогрессирования, клиника, диагностика, лечение. Современная ревматология. 2019;13(2):9-21. doi:10.14412/1996-7012-2019-2-9-21; Bruyere O, Cooper C, Pelletier JP, et al. An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: a report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Semin Arthritis Rheum. 2014 Dec;44(3):253-63. doi:10.1016/j.semarthrit.2014.05.014. Epub 2014 May 14.; Bruyere O, Cooper C, Pelletier JP, et al. A consensus statement on the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) algorithm for the management of knee osteoarthritis-From evidence-based medicine to the real-life setting. Semin Arthritis Rheum. 2016 Feb;45(4 Suppl):S3–11. doi:10.1016/j.semarthrit.2015.11.010.; Bruyere O, Honvo G, Veronese N, et al. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Semin Arthritis Rheum. 2019 Apr 30. pii: S0049–0172(19)30043–5. doi:10.1016/j.semarthrit.2019.04.008.; Лила АМ, Ткачева ОН, Наумов АВ и др. Место и роль парентеральной формы хондроитина сульфата в терапии остеоартрита: мультидисциплинарный консенсус. Русский медицинский журнал. 2021;(6):68-74; Goldriring MB. The role of the chondrocyte in osteoarthritis. Arthritis Rheum. 2000 Sep;43(9):1916-26. doi:10.1002/1529-0131(200009)43:93.0.CO;2-I.; Ronca F, Palmieri L, Panicucci P, et al. Anti-inflammatory activity of chondroitin sulfate. Osteoarthritis Cartilage. 1998 May;6 Suppl A:14-21. doi:10.1016/s1063-4584(98)80006-x.; Alaeddine N, Olee T, Hashimoto S, et al. Production of the chemokine RANTES by articular chondrocytes and role in cartilage degradation. Arthritis Rheum. 2001 Jul;44(7): 1633-43. doi:10.1002/1529-0131(200107)44:73.0.CO;2-Z.; Lambert C, Mathy-Hartert M, Dubuc JE, et al. Characterization of synovial angiogenesis in osteoarthritis patients and its modulation by chondroitin sulfate. Arthritis Res Ther. 2012 Mar 12;14(2):R58. doi:10.1186/ar3771.; Tat SK, Pelletier JP, Verges J, et al. Chondroitin and glucosamine sulfate in combination decrease the pro-resorptive properties of human osteoarthritis subchondral bone osteoblasts: a basic science study. Arthritis Res Ther. 2007;9(6):R117. doi:10.1186/ar2325.; Leeb BF, Schweitzer H, Montag K, Smolen JS. A meta-analysis of chondroitin sulfate in the treatment of osteoarthritis. Osteoarthritis Cartilage. 1999;7(Suppl A):130.; Eugenio-Sarmiento RM, Vanapat DHD, Salido EJ. The efficacy of chondroitinsulfate in the treatment of knee osteoarthritis: a metaanalysis. Osteoarthritis Cartilage. 1999;7 (Suppl A):139.; Schneider H. Sympptom-Modifying Effect of Chondroitin Sulfate in Knee Osteoarthritis: A Meta-Analysis of Randomized PlaceboControlled Trials Performed with Structum. Open Rheumatol J. 2012;6:183-9. doi:10.2174/1874312901206010183. Epub 2012 Jul 25.; Singh JA, Noorbaloochi S, MacDonald R, Maxwell LJ. Chondroitin for osteoarthritis (Rewiew). Cochrane Database Syst Rev. 2015 Jan 28;1:CD005614. doi:10.1002/14651858.CD005614.pub2.; Beaudart C, Lengele L, Leclercq V, et al. Symptomatic Efficacy of Pharmacological Treatments for Knee Osteoarthritis: A Systematic Review and a Network Meta-Analysis with a 6-Month Time Horizon. Drugs. 2020 Dec;80(18):1947-59. doi:10.1007/s40265-020-01423-8; Henrotin Y, Marty M, Mobasheri A. What is the current status of chondroitin sulfate and glucosamine for the treatment of knee osteoarthritis? Maturitas. 2014 Jul;78(3): 184-7. doi:10.1016/j.maturitas.2014.04.015. Epub 2014 May 1.; Клинические рекомендации МЗ РФ 2020 г. Хроническая боль у пациентов пожилого и старческого возраста.; Lee YH. Chondroitin sulfate is superior to placebo in symptomatic knee osteoarthritis. Ann Rheum Dis. 2017 Oct 9. pii: annrheumdis2017-212452. doi:10.1136/annrheumdis2017-212452. [Epub ahead of print].; Алексеева ЛИ, Архангельская ГС, Давыдова АФ и др. Отдаленные результаты применения структума (по материалам многоцентрового исследования). Терапевтический архив. 2003;(9):82-6.; Торшин ИЮ, Лила АМ, Лиманова ОА, Громова ОА. Перспективы применения хондроитина сульфата и глюкозамина сульфата при остеоартрите в сочетании с патологией почек и мочевыделительной системы. Фармакоэкономика. Современная Фармакоэкономика и Фармакоэпидемиология. 2020;13(1):23-34.; Громова ОА, Торшин ИЮ, Зайчик БЦ и др. О различиях в стандартизации лекарственных препаратов на основе экстрактов хондроитина сульфата. Фармакоэкономика. Современная Фармакоэкономика и Фармакоэпидемиология. 2021; 14(1):51-62. doi: 10.06.2021/19.07.2021/21.07.2021; Лила АМ, Громова ОА, Торшин ИЮ и др. Молекулярные эффекты хондрогарда при остеоартрите и грыжах межпозвоночного диска. Неврология, нейропсихиатрия, психосоматика. 2017;9(3):88-97. doi:10.14412/2074-2711-2017-3-88-97.; Шарапова ЕП, Кашеварова НГ, Таскина ЕА и др. Исследование эффективности, переносимости и безопасности препарата Хондрогард у пациентов с остеоартрозом коленных суставов и коморбидностью. Фарматека. 2017;(7):46-51.; Торшин ИЮ, Лила АМ, Наумов АВ и др. Метаанализ клинических исследований эффективности лечения остеоартита препаратом Хондрогард. Фармакоэкономика. Современная Фармакоэкономика и Фармакоэпидемиология. 2020;13(4):399-410.; Алексеева ЛИ, Шарапова ЕП, Кашеварова НГ, Таскина ЕА. Сравнительное исследование эффективности и безопасности препарата Хондрогард® при комбинированном (внутрисуставное и внутримышечное) и внутримышечном введении у пациентов с остеоартритом коленных суставов. Современная ревматология. 2018;12(2):44-9. doi:10.14412/19967012-2018-2-44-49; Паникар ВИ, Коршун ЕИ, Аникин СГ и др. Персонализированная программа реабилитации пациентов старшего возраста с остеоартритом. Современная ревматология. 2021;15(3):69-74. doi:10.14412/1996-7012-2021-3-69-74; https://mrj.ima-press.net/mrj/article/view/1181

الاتاحة: https://mrj.ima-press.net/mrj/article/view/1181
https://doi.org/10.14412/1996-7012-2021-4-120-125

المؤلفون: E. P. Sharapova, L. I. Alekseeva, E. A. Taskina, N. G. Kashevarova, S. G. Anikin, E. A. Strebkova, A. M. Lila, V. I. Mazurov, N. A. Shostak, E. I. Shmidt, E. P. Ilivanova, Е. П. Шарапова, Л. И. Алексеева, Е. А. Таскина, Н. Г. Кашеварова, С. Г. Аникин, Е. А. Стребкова, А. М. Лила, В. И. Мазуров, Н. А. Шостак, Е. И. Шмидт, Е. П. Иливанова

المصدر: Modern Rheumatology Journal; Том 14, № 1 (2020); 67-73 ; Современная ревматология; Том 14, № 1 (2020); 67-73 ; 2310-158X ; 1996-7012 ; 10.14412/1996-7012-2020-1

مصطلحات موضوعية: безопасность, comorbidity, extended-release symptomatic drugs, alflutop, efficacy, safety, коморбидность, симптоматические препараты замедленного действия, алфлутоп, эффективность

وصف الملف: application/pdf

Relation: https://mrj.ima-press.net/mrj/article/view/995/954; Allen KD, Choong PF, Davis AM, et al. OA: Models for appropriate care across the disease continuum. Best Pract Res Clin Rheumatol. 2016 Jun;30(3):503-35. doi:10.1016/j.berh.2016.09.003; Arden N, Nevit MC. Osteoarthritis: Epidemiology. Best Pract Res Clin Rheumatol. 2006;20(1):3-25. doi:10.1016/j.berh.2005.09.007; Галушко ЕА. Медико-социальная значимость ревматических заболеваний: Автореф. дисс. … докт. мед. наук. Москва; 2011.; Лила АМ, Лила ВА. Социальная значимость и экономические последствия ревматических заболеваний. Гигиена и санитария. 2017;96(4):387-92.; Neogi T, Zhang Y. Epidemiology of OA. Rheum Dis Clin North Am. 2013 Feb;39(1): 1-19. doi:10.1016/j.rdc.2012.10.004; Feinstein AR. Pre-therapeutic classification of co-morbidity in chronic disease. J Chron Dis. 1970;23(7):455-68. doi:10.1016/ 0021-9681(70)90054-8; Kraemer HC. Statistical issues in assessing comorbidity. Stat Med. 1995;14:721-3. doi:10.1002/sim.4780140803; Van den Akker M, Buntinx F, Roos S, Knottnerus JA. Comorbidity or multimorbidity: what is in a name? A review of the literature. Eur J Gen Pract. 1996;2(2):65-70. doi:10.3109/13814789609162146; Boureau F, Schneid H, Zeghari N, et al. The IPSO study: ibuprofen, paracetamol study in osteoarthritis. A randomized comparative clinical study comparing the efficacy and safety of ibuprofen and paracetamol analgesic treatment of osteoarthritis of knee or hip. Ann Rheum Dis. 2004;63:1028-35. doi:10.1136/ard.2003.011403; Bruyere O, Cooper C, Pelletier JP, et al. An algorithm recommendation for the management of knee OA in Europe and internationally: a report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and OA (ESCEO). Semin Arthritis Rheum. 2014;44:253-63. doi:10.1016/j.semarthrit.2014.05.014; McAlindon TE, LaValley MP, Gulin JP, Felson DT. Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis. JAMA. 2000 Mar 15;283(11):1469-75. doi:10.1001/jama. 283.11.1469; Henrotin Y, Marty M, Mobasheri A. What is the current status of chondroitin sulfate and glucosamine for the treatment of knee osteoarthritis? Maturitas. 2014;78:184-7. doi:10.1016/j.maturitas.2014.04.015; Алексеева ЛИ, Шарапова ЕП, Таскина ЕА и др. Многоцентровое слепое рандомизированное плацебоконтролируемое исследование симптом- и структурно-модифицирующего действия препарата алфлутоп у больных остеоартрозом коленных суставов. Сообщение 1 – оценка симптом-модифицирующего действия препарата. Научно-практическая ревматология. 2013;51(5):532-8. doi:10.14412/1995-4484-2013-1545.; Алексеева ЛИ, Шарапова ЕП, Таскина ЕА и др. Многоцентровое слепое рандомизированное плацебоконтролируемое исследование симптом- и структурно-модифицирующего действия препарата алфлутоп у больных остеоартрозом коленных суставов. Сообщение 2 – оценка структурно-модифицирующего действия препарата. Научно-практическая ревматология. 2014;52(2):174-7. doi:10.14412/1995-4484-2014-174-177.; Алексеева ЛИ, Таскина ЕА, Лила АМ и др. Многоцентровое проспективное рандомизированное исследование эффективности и безопасности препарата Алфлутоп® в альтернирующем режиме по сравнению со стандартным режимом. Сообщение 1: оценка эффективности препарата при различных схемах применения. Современная ревматология. 2019;13(3): 51-9. doi:10.14412/1996-7012-2019-3-51-59.; Гроппа Л, Мынзату И, Карасава М и др. Эффективность алфлутопа у больных деформирующим артрозом. Клиническая ревматология. 1995;(3):20-2.; Лукина ГВ, Сигидин ЯА. Опыт применения препарата алфлутоп в лечении остеоартроза. Научно-практическая ревматология. 1996;34(4):40-3.; Лукина ГВ, Сигидин ЯА. Хондропротективный препарат алфлутоп в лечении остеоартроза. Научно-практическая ревматология. 2001;(2):51-3. doi:10.14412/ 1995-4484-2001-400.; Коршунов НИ, Марасаев ВВ, Баранова ЭЯ и др. Роль воспаления и оценка хондропротективного действия Алфлутопа у больных с остеоартрозом по данным магнитно-резонансной томографии коленного сустава. Русский медицинский журнал. 2003;11(2):13-20.; Чичасова НВ, Имаметдинова ГР, Шевченко ОВ. Инъекционная терапия остеоартроза. Качество жизни. Медицина. Болезни костно-мышечной системы. 2003;(3):69-72.; Чичасова НВ. Место медленно действующих препаратов в рациональной терапии деформирующего остеоартроза. Consilium Medicum. 2005;7(8):634-8.; Светлова МС, Игнатьева ВК. Применение алфлутопа в лечении больных остеоартрозом. Клиническая медицина. 2004;(6):52-5.; Дроздов ВН, Коломиец ЕВ. Применение алфлутопа у больных остеоартрозом с гастропатией, развившейся на фоне лечения НПВП. Фарматека. 2005;(20):125-8.; Левин ОС, Олюнин ДЮ, Голубева ЛВ. Эффективность алфлутопа при хронической вертеброгенной люмбоишиалгии по данным двойного слепого плацебо-контролируемого исследования. Научно-практическая ревматология. 2004;42(4):80-4. doi:10.14412/1995-4484-2004-809.; Левин ОС, Маросейкин ТВ, Казакова ТВ и др. Эффективность алфлутопа при вертеброгенной цервикобрахиалгии. Фарматека. 2008;(6):48-54.; https://mrj.ima-press.net/mrj/article/view/995

الاتاحة: https://mrj.ima-press.net/mrj/article/view/995
https://doi.org/10.14412/1996-7012-2020-1-67-73

المؤلفون: L. I. Alekseeva, E. A. Taskina, N. G. Kashevarova, E. P. Sharapova, E. A. Strebkova, S. G. Anikin, N. V. Chichasova, T. A. Raskina, E. V. Zonova, E. N. Otteva, E. I. Shmidt, S. P. Yakupova, I. B. Vinogradova, O. N. Ivanova, V. A. Lila, B. V. Zavadovsky, P. A. Shesternya, A. M. Lila, Л. И. Алексеева, Е. А. Таскина, Н. Г. Кашеварова, Е. П. Шарапова, Е. А. Стребкова, С. Г. Аникин, Н. В. Чичасова, Т. А. Раскина, Е. В. Зонова, Э. Н. Оттева, Е. И. Шмидт, С. П. Якупова, И. Б. Виноградова, О. Н. Иванова, В. А. Лила, Б. В. Завадовский, П. А. Шестерня, А. М. Лила

المساهمون: Исследование выполнено в рамках научной темы № НИОКТР АААА-А19-119021190150-6 «Разработка методов комплексной терапии заболеваний костно-мышечной системы».

المصدر: Modern Rheumatology Journal; Том 15, № 1 (2021); 51-59 ; Современная ревматология; Том 15, № 1 (2021); 51-59 ; 2310-158X ; 1996-7012

مصطلحات موضوعية: гликозаминогликан-пептидный комплекс, comorbidities, glycosaminoglycan-peptide complex, коморбидные заболевания

وصف الملف: application/pdf

Relation: https://mrj.ima-press.net/mrj/article/view/1089/1073; Strauss WL Jr, Cave AJE. Pathology and the posture of Neanderthal man. Q Rev Biol. 1957 Dec;32(4):348-63. doi:10.1086/401979.; Heberden W. Commentaries on the History and Cure of Diseases. London: T. Payne; 1802.; Sandifort E. Museum Anatomicum Academiae Lugduno-Batavae. Vol. 2. Leiden: University of Leiden; 1793. Table LXIV.; Haygarth J. A clinical history of the nodosity of the joints. London: Gadell and Davies; 1805.; Brodie BC. Pathological and Surgical Observations on the Diseases of the Joints. 2nd ed. London: Longman, Hurst, Rees, Orne and Brown; 1822.; Garrod AE. A Treatise of Rheumatism and Rheumatoid Arthritis. London: Griffin; 1890.; Willy C, Schneider P, Engelhardt M, et al. Richard von Volkmann: surgeon and Renaissance man. Clin Orthop Relat Res. 2008 Feb;466(2):500-6. doi:10.1007/s11999-007-0007-4. Epub 2008 Jan 10.; Forsbrook WH. A Dissertation on Osteoarthritis. London: H.K. Lewis; 1893.; Алексеева ЛИ, Таскина ЕА, Кашеварова НГ. Остеоартрит: эпидемиология, классификация, факторы риска и прогрессирования, клиника, диагностика, лечение. Современная ревматология. 2019;13(2):9-21. doi:10.14412/1996-7012-2019-2-9-21; Лила АМ, Алексеева ЛИ, Таскина ЕА. Современные подходы к терапии остеоартрита с учетом обновленных международных рекомендаций. Русский медицинский журнал. Медицинское обозрение. 2019;3(11-2):48-52.; Veronese N, Cereda E, Maggi S, et al. Osteoarthritis and mortality: A prospective cohort study and systematic review with meta-analysis. Semin Arthritis Rheum. 2016 Oct;46(2):160-7. doi:10.1016/j.semarthrit.2016.04.002.; Kovari E, Kaposi A, Bekes G, et al. Comorbidity clusters in generalized osteoarthritis among female patients: A crosssectional study. Semin Arthritis Rheum. 2019 Sep 9. pii: S0049-0172(19)30233-1. doi:10.1016/j.semarthrit.2019.09.001.; Adler E, Wolf E, Taustein I. A double blind trial with cartilage and bone marrow extract in degenerative gonarthrosis. Acta Rheumatol Scand. 1970;16(1):6-11.; Katona G. A clinical trial of glycosaminoglycan-peptide complex (Rumalon) in patients with osteoarthritis of the knee. Curr Med Res Opin. 1987;10(9):625-33. doi:10.1185/03007998709112416.; Gramajo RJ, Cutroneo EJ, Fernandez DE, et al. A single-blind, placebo-controlled study of glycosaminoglycan-peptide complex (Rumalon) in patients with osteoarthritis of the hip or knee. Curr Med Res Opin. 1989; 11(6): 366-73. doi:10.1185/03007998909110137.; Алексеева ЛИ, Карякин АН, Смирнов АВ, Беневоленская ЛИ. Применение Румалона при гонартрозе. Терапевтический архив. 1997;(5):64-6.; Наумов АВ, Ткачева ОН, Котовская ЮВ, Ховасова НО. Эффективность и безопасность гликозаминогликанпептидного комплекса в терапии обострений хронической боли при остеоартрите коленных суставов у коморбидных больных (результаты наблюдательной программы ДАРТС). Лечащий врач. 2018;(7):2-7.; Каратеев АЕ, Алексеева ЛИ, Лила АМ и др. Оценка эффективности и безопасности гликозаминогликан-пептидного комплекса при лечении остеоартрита коленного сустава у больных с предшествующей неэффективностью пероральных медленно действующих противовоспалительных препаратов (многоцентровое открытое исследование ПРИМУЛА: Применение Румалона® при Исходно Малом Успехе в Лечении остеоАртрита). Научнопрактическая ревматология. 2018; 56(1):22-7.; Алексеева ЛИ, Каратеев АЕ, Погожева ЕЮ и др. Оценка эффективности и безопасности инъекционной формы гликозаминогликан-пептидного комплекса у пациентов с остеоартритом: многоцентровое наблюдательное исследование ГЛАДИОЛУС (ГПК при Лечении остеоАртрита: Динамическое Исследование Обезболивания и Локального Уменьшения Симптомов). Современная ревматология. 2020;14(2):76–83. doi:10.14412/1996-7012-2020-2-76-83.; Schacht E, Roetz R. Answer: Nephrotic syndrome after injections of bovine cartilage and marrow extract. Lancet. 1989 Apr 29; 1(8644):963. doi:10.1016/s0140-6736(89)92547-6.; https://mrj.ima-press.net/mrj/article/view/1089

الاتاحة: https://mrj.ima-press.net/mrj/article/view/1089
https://doi.org/10.14412/1996-7012-2021-1-51-59

المؤلفون: E. V. Chetina, E. P. Sharapova, Е. В. Четина, Е. П. Шарапова

المصدر: Modern Rheumatology Journal; Том 14, № 1 (2020); 93-100 ; Современная ревматология; Том 14, № 1 (2020); 93-100 ; 2310-158X ; 1996-7012 ; 10.14412/1996-7012-2020-1

مصطلحات موضوعية: остеоартрит, molecular markers, postoperative pain, rheumatoid arthritis, osteoarthritis, молекулярные маркеры, постоперационная боль, ревматоидный артрит

وصف الملف: application/pdf

Relation: https://mrj.ima-press.net/mrj/article/view/999/958; Tchetina EV, Semyonova LA. Genetic mechanisms of cartilage degradation in the development and osteoarthritis. In: Protein Purification and Analysis III – Methods and applications; edited by iConcept Press; ISBN 978-1-922227-65-2; iConcept Press Ltd.; Buckwalter JA, Saltzman C, Brown T. The impact of osteoarthritis: implications for research. Clin Orthop Relat Res. 2004;427(Suppl): S6-15. doi:10.1097/01.blo.0000143938.30681.9d; Dean DD, Azzo W, Martel-Pelletier J, et al. Evidence for metalloproteinase and metalloproteinase inhibitor imbalance in human osteoarthritic cartilage. J Clin Invest. 1989;84(2): 678-85. doi:10.1172/JCI114215; Muller B. Cytokine imbalance in nonimmunological chronic disease. Cytokine. 2002;18(6):334-9. doi:10.1006/cyto.2002.0882; Aigner T, Rose J, Martin J, Buckwalter J. Aging theories of primary osteoarthritis: from epidemiology to molecular biology. Rejuvenation Res. 2004;7(2):134-45. doi:10.1089/1549168041552964; Lorenzo P, Bayliss MT, Heinegard D. Altered patterns and synthesis of extracellular matrix macromolecules in early osteoarthritis. Matrix Biol. 2004;23(6):381-91. doi:10.1016/j.matbio.2004.07.007; Sharif M, Whitehouse A, Sharman P, et al. Increased apoptosis in human osteoarthritic cartilage corresponds to reduced cell density and expression of caspase 3. Arthritis Rheum. 2004;50(2):507-15. doi:10.1002/art.20020; Clauw DJ, Witter J. Pain and rheumatology: thinking outside the joint. Arthritis Rheum. 2009;60(2):321-4. doi:10.1002/art.24326; Stoppiello LA, Mapp PI, Wilson D, et al. Structural associations of symptomatic knee osteoarthritis. Arthritis Rheum. 2014;66(11): 3018-27. doi:10.1002/art.38778; Poole AR, Guilak F, Abramson SB. Etiopathogenesis of osteoarthritis. In: Moskowitz RW, Altman RD, Hochberg MC, et al, eds. Osteoarthritis: Diagnosis and Medical/ Surgical Management. 4th ed. Lippincott, PA: Williams &Wilkins; 2007. P. 27-49.; Sofat N, Ejindu V, Kiely P. What makes osteoarthritis painful? The evidence for local and central pain processing. Rheumatology (Oxford). 2011;50(12):2157-65. doi:10.1093/rheumatology/ker283; Lee AS, Ellman MB, Yan D, et al. A current review of molecular mechanisms regarding osteoarthritis and pain. Gene. 2013; 527(2):440-7. doi:10.1016/j.gene. 2013.05.069 13. Saito T. Neurogenic inflammation in osteoarthritis of the knee. Mod Rheumatol. 2003;13(4):301-4. doi:10.3109/s10165-003-0253-6; Orita S, Ishikawa T, Miyagi M, et al. Pain-related sensory innervation in monoiodoacetate-induced osteoarthritis in rat knees that gradually develops neuronal injury in addition to inflammatory pain. BMC Musculoskelet Disord. 2011;12:134. doi:10.1186/1471-2474-12-134; Moreton BJ, Tew V, das Nair R, et al. Pain phenotype in patients with knee osteoarthritis: classification and measurement properties of painDETECT and self-report Leeds assessment of neuropathic symptoms and signs scale in a cross-sectional study. Arthritis Care Res (Hoboken). 2015;67(4): 519-28. doi:10.1002/acr.22431; Ordeberg G. Characterization of joint pain in human OA. Novartis Found Symp. 2004;260:105-15; discussion 115-21, 277-9.; Gossec L, Paternotte S, Aanerud GJ, et al. Finalization and validation of the rheumatoid arthritis impact of disease score, a patientderived composite measure of impact of rheumatoid arthritis: a EULAR initiative. Ann Rheum Dis. 2011;70(6): 935-42. doi:10.1136/ard.2010.142901; Nijs J, Kosek E, van Oosterwijck J, Meeus M. Dysfunctional endogenous analgesia during exercise in patients with chronic pain: to exercise or not to exercise? Pain Physician. 2012;15(3):205-13.; Daien CI, Hua C, Combe B, Landewe R. Non-pharmacological and pharmacological interventions in patients with early arthritis: a systematic literature review informing the 2016 update of EULAR recommendations for the management of early arthritis. RMD Open. 2017;3(1):e000404. doi:10.1136/rmdopen2016-000404; Ossipov MH. The perception and endogenous modulation of pain. Scientifica (Cairo). 2012;2012:561761. doi:10.6064/2012/561761; Fitzcharles MA, Shir Y. Management of chronic pain in the rheumatic diseases with insights for the clinician. Ther Adv Musculoskelet Dis. 2011;3(4):179-90. doi:10.1177/1759720X11408999; Kidd BL, Urban LA. Mechanisms of inflammatory pain. Br J Anaesth. 2001;87(1): 3-11. doi:10.1093/bja/87.1.3; Treede RD, Jensen TS, Campbell JN, et al. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology. 2008;70(18):1630-5. doi:10.1212/01.wnl.0000282763.29778.59; Walsh DA, Mapp PI, Kelly S. Calcitonin gene-related peptide in the joint: contributions to pain and inflammation. Br J Clin Pharmacol. 2015;80(5):965-78. doi:10.1111/bcp.12669; Reichling DB, Green PG, Levine JD. The fundamental unit of pain is the cell. Pain. 2013;154(1):S2-9. doi:10.1016/j.pain.2013.05.037; Campbell JN, Meyer RA. Mechanisms of neuropathic pain. Neuron. 2006;52(1):77-92. doi:10.1016/j.neuron.2006.09.021; Akinci A, Al Shaker M, Chang MH, et al. Predictive factors and clinical biomarkers for treatment in patients with chronic pain caused by osteoarthritis with a central sensitisation component. Int J Clin Pract. 2016;70(1):31-44. doi:10.1111/ijcp.12749; Latremoliere A, Woolf CJ. Central sensitization: a generator of pain hypersensitivity by central neural plasticity. J Pain. 2009; 10(8):895-926. doi:10.1016/j.jpain.2009.06.012; Nijs J, van Houdenhove B, Oostendorp RA. Recognition of central sensitization in patients with musculoskeletal pain: Application of pain neurophysiology in manual therapy practice. Man Ther. 2010;15(2):135-41. doi:10.1016/j.math.2009.12.001; Omoigui S. The biochemical origin of pain – proposing a new law of pain: the origin of all pain is inflammation and the inflammatory response. Part 1 of 3-a unifying law of pain. Med Hypotheses. 2007;69(1): 70-82. doi:10.1016/j.mehy.2006.11.028; Ren K, Dubner R. Interactions between the immune and nervous systems in pain. Nat Med. 2010;16(11):1267-76. doi:10.1038/nm.2234; Edwards RR, Wasan AD, Bingham CO 3rd, et al. Enhanced reactivity to pain in patients with rheumatoid arthritis. Arthritis Res Ther. 2009;11(3):R61. doi:10.1186/ar2684; Jakobsson U, Hallberg IR. Pain and quality of life among older people with rheumatoid arthritis and/or osteoarthritis: a literature review. J Clin Nurs. 2002;11(4):430-43. doi:10.1046/j.1365-2702.2002.00624.x; Davis MC, Zautra AJ, Younger J, et al. Chronic stress and regulation of cellular markers of inflammation in rheumatoid arthritis: implications for fatigue. Brain Behav Immun. 2008;22(1):24-32. doi:10.1016/j.bbi. 2007.06.013; Lee YC, Frits ML, Iannaccone CK, et al. Subgrouping of patients with rheumatoid arthritis based on pain, fatigue, inflammation, and psychosocial factors. Arthritis Rheum. 2014;66(8):2006-14. doi:10.1002/art.38682; Lee YC, Chibnik LB, Lu B, et al. The relationship between disease activity, sleep, psychiatric distress and pain sensitivity in rheumatoid arthritis: a cross-sectional study. Arthritis Res Ther. 2009;11(5):R160. doi:10.1186/ar2842; Ranzolin A, Brenol JC, Bredemeier M, et al. Association of concomitant fibromyalgia with worse disease activity score in 28 joints, health assessment questionnaire, and short form 36 scores in patients with rheumatoid arthritis. Arthritis Rheum. 2009;61(6):794-800. doi:10.1002/art.24430; Geenen R, van Middendorp H, Bijlsma JW. The impact of stressors on health status and hypothalamic-pituitary-adrenal axis and autonomic nervous system responsiveness in rheumatoid arthritis. Ann N Y Acad Sci. 2006; 1069:77-97. doi:10.1196/annals.1351.007; Lee YC, Lu B, Edwards RR, et al. The role of sleep problems in central pain processing in rheumatoid arthritis. Arthritis Rheum. 2013;65(1):59-68. doi:10.1002/art.37733; Stack RJ, van Tuyl LH, Sloots M, et al. Symptom complexes in patients with seropositive arthralgia and in patients newly diagnosed with rheumatoid arthritis: a qualitative exploration of symptom development. Rheumatology (Oxford). 2014;53(9):1646-53. doi:10.1093/rheumatology/keu159; Altawil R, Saevarsdottir S, Wedren S, et al. Remaining pain in early rheumatoid arthritis patients treated with methotrexate. Arthritis Care Res (Hoboken). 2016;68(8):1061-8. doi:10.1002/acr.22790; Lee YC, Nassikas NJ, Clauw DJ. The role of the central nervous system in the generation and maintenance of chronic pain in rheumatoid arthritis, osteoarthritis and fibromyalgia. Arthritis Res Ther. 2011;13(2): 211. doi:10.1186/ar3306; Woolf CJ. Central sensitization: implications for the diagnosis and treatment of pain. Pain. 2011;152(3):S2-15. doi:10.1016/j.pain.2010.09.030; Di Franco M, Guzzo MP, Spinelli FR, et al. Pain and systemic lupus erythematosus. Reumatismo. 2014;66(1):33-8. doi:10.4081/reumatismo.2014.762; Malfait AM, Schnitzer TJ. Towards a mechanism-based approach to pain management in osteoarthritis. Nat Rev Rheumatol. 2013;9(11):654-64. doi:10.1038/nrrheum.2013.138; Zois CD, Katsanos KH, Kosmidou M, Tsianos EV. Neurologic manifestations in inflammatory bowel diseases: current knowledge and novel insights. J Crohns Colitis. 2010;4(2):115-24. doi:10.1016/j.crohns.2009.10.005; Yunus MB. The prevalence of fibromyalgia in other chronic pain conditions. Pain Res Treat. 2012;2012:584573. doi:10.1155/2012/584573; Abdelhamid RE, Sluka KA. ASICs mediate pain and inflammation in musculoskeletal diseases. Physiology (Bethesda). 2015;30(6): 449-59. doi:10.1152/physiol.00030.2015; Westlund KN, Kochukov MY, Lu Y, McNearney TA. Impact of central and peripheral TRPV1 and ROS levels on proinflammatory mediators and nociceptive behavior. Mol Pain. 2010;6(1):46. doi:10.1186/1744-8069-6-46; Yamaga M, Tsuji K, Miyatake K, et al. Osteopontin level in synovial fluid is associated with the severity of joint pain and cartilage degradation after anterior cruciate ligament rupture. PLoS One. 2012;7(11):e49014. doi:10.1371/journal.pone.0049014; Walsh DA, McWilliams DF, Turley MJ, et al. Angiogenesis and nerve growth factor at the osteochondral junction in rheumatoid arthritis and osteoarthritis. Rheumatology (Oxford). 2010;49(10):1852-61. doi:10.1093/rheumatology/keq188; Barthel C, Yeremenko N, Jacobs R, et al. Nerve growth factor and receptor expression in rheumatoid arthritis and spondyloarthritis. Arthritis Res Ther. 2009;11(3):R82. doi:10.1186/ar2716; O’Rourke KP, O’Donoghue G, Adams C, et al. High levels of Lymphotoxin-Beta (LT-Beta) gene expression in rheumatoid arthritis synovium: clinical and cytokine correlations. Rheumatol Int. 2008;28(10):979-86. doi:10.1007/s00296-008-0574-z; Richardson D, Pearson RG, Kurian N, et al. Characterization of the cannabinoid receptor system in synovial tissue and fluid in patients with osteoarthritis and rheumatoid arthritis. Arthritis Res Ther. 2008;10(2):R43. doi:10.1186/ar2401; Mousa SA, Straub RH, Schä fer M, Stein C. Beta-endorphin, Met-enkephalin and corresponding opioid receptors within synovium of patients with joint trauma, osteoarthritis and rheumatoid arthritis. Ann Rheum Dis. 2007;66(7):871-9. doi:10.1136/ard.2006.067066; Louati K, Berenbaum F. Fatigue in chronic inflammation – a link to pain pathways. Arthritis Res Ther. 2015;17:254. doi:10.1186/s13075-015-0784-1; Clark AK, Staniland AA, Malcangio M. Fractalkine/CX3CR1 signalling in chronic pain and inflammation. Curr Pharm Biotechnol. 2011;12:1707-14. doi:10.2174/138920111798357465; Chen YM, Chen HH, Lan JL, Chen DY. Improvement of cognition, a potential benefit of anti-TNF therapy in elderly patients with rheumatoid arthritis. Joint Bone Spine. 2010; 77(4):366-7. doi:10.1016/j.jbspin.2010.01.017; Clark IA, Vissel B. Excess cerebral TNF causing glutamate excitotoxicity rationalizes treatment of neurodegenerative diseases and neurogenic pain by anti-TNF agents. J Neuroinflammation. 2016;13(1):236. doi:10.1186/s12974-016-0708-2; Hess A, Axmann R, Rech J, et al. Blockade of TNF-α rapidly inhibits pain responses in the central nervous system. Proc Natl Acad Sci U S A. 2011;108(9):3731-6. doi:10.1073/pnas.1011774108; Kosek E, Altawil R, Kadetoff D, et al. Evidence of different mediators of central inflammation in dysfunctional and inflammatory pain – interleukin-8 in fibromyalgia and interleukin-1β in rheumatoid arthritis. J Neuroimmunol. 2015;280:49-55. doi:10.1016/j.jneuroim.2015.02.002; Lisowska B, Maslinski W, Maldyk P, et al. The role of cytokines in inflammatory response after total knee arthroplasty in patients with rheumatoid arthritis. Rheumatol Int. 2008; 28(7):667-71. doi:10.1007/s00296-007-0508-1; Attur MI, Belitskaya-Levy C, Krasnokutsky S, et al. Increased interleukin1β gene expression in peripheral blood leukocytes is associated with increased pain and predicts risk for progression of symptomatic knee osteoarthritis. Arthritis Rheum. 2011; 63(7):1908-17. doi:10.1002/art.30360; Prochazkova M, Zanvit P, Dolezal T, et al. Increased gene expression and production of spinal cyclooxygenase 1 and 2 during experimental osteoarthritis pain. Physiol Res. 2009; 58(3):419-25.; Vardeh D, Wang D, Costigan M, et al. COX2 in CNS neural cells mediates mechanical inflammatory pain hypersensitivity in mice. J Clin Invest. 2009;119(2):287-94. doi:10.1172/JCI37098; Leichsenring A, Bä cker I, Wendt W, et al. Differential expression of Cathepsin S and X in the spinal cord of a rat neuropathic pain model. BMC Neurosci. 2008;9:80. doi:10.1186/1471-2202-9-80; Kawasaki Y, Xu ZZ, Wang X, et al. Distinct roles of matrix metalloproteases in the early- and late-phase development of neuropathic pain. Nat Med. 2008;14(3): 331-6. doi:10.1038/nm1723; McDougall JJ, Schuelert N, Bowyer J. Cathepsin K inhibition reduces CTXII levels and joint pain in the guinea pig model of spontaneous osteoarthritis. Osteoarthritis Cartilage. 2010;18(10):1355-7. doi:10.1016/ j.joca.2010.07.014; Ohtori S, Takahashi K, Moriya H, Myers RR. TNF-alpha and TNF-alpha receptor type 1 upregulation in glia and neurons after peripheral nerve injury: studies in murine DRG and spinal cord. Spine (Phila Pa 1976). 2004;29(10):1082-8. doi:10.1097/00007632-200405150-00006 7; Moon SJ, Woo YJ, Jeong JH, et al. Rebamipide attenuates pain severity and cartilage degeneration in a rat model of osteoarthritis by downregulating oxidative damage and catabolic activity in chondrocytes. Osteoarthritis Cartilage. 2012;20(11): 1426-38. doi:10.1016/j.joca.2012.08.002; Lee J, Hong YS, Jeong JH, et al. Coenzyme Q10 ameliorates pain and cartilage degradation in a rat model of osteoarthritis by regulating nitric oxide and inflammatory cytokines. PLoS One. 2013;8(7):e69362. doi:10.1371/journal.pone.0069362; Ji RR, Xu ZZ, Wang X, Lo EH. Matrix metalloprotease regulation of neuropathic pain. Trends Pharmacol Sci. 2009;30(7): 336-40. doi:10.1016/j.tips.2009.04.002; Tejima E, Guo S, Murata Y, et al. Neuroprotective effects of overexpressing tissue inhibitor of metalloproteinase TIMP-1. J Neurotrauma. 2009;26(11):1935-41. doi:10.1089/neu.2009-0959; Franses RE, McWilliams DF, Mapp PI, Walsh DA. Osteochondral angiogenesis and increased protease inhibitor expression in OA. Osteoarthritis Cartilage. 2010;18(4):563-71. doi:10.1016/j.joca.2009.11.015; Lyu D, Yu W, Tang N, et al. The mTOR signaling pathway regulates pain-related synaptic plasticity in rat entorhinal-hippocampal pathways. Mol Pain. 2013;9:64. doi:10.1186/1744-8069-9-64; Jiang F, Hua LM, Jiao YL, et al. Activation of mammalian target of rapamycin contributes to pain nociception induced in rats by BmK I, a sodium channel-specific modulator. Neurosci Bull. 2014;30(1):21-32. doi:10.1007/s12264-013-1377-0; Melemedjian OK, Khoutorsky A, Sorge RE, et al. mTORC1 inhibition induces pain via IRS-1-dependent feedback activation of ERK. Pain. 2013;154(7):1080-91. doi:10.1016/j.pain.2013.03.021; Geranton SM, Jimenez-Diaz L, Torsney C, et al. A rapamycin-sensitive signaling pathway is essential for the full expression of persistent pain states. J Neurosci. 2009;29(47):15017-27. doi:10.1523/JNEUROSCI.3451-09.2009; Price TJ, Dussor G. AMPK: An emerging target for modification of injury-induced pain plasticity. Neurosci Lett. 2013;557(Pt A):9-18. doi:10.1016/j.neulet.2013.06.060; Blaney Davidson EN, van Caam AP, Vitters EL, et al. TGF-β is a potent inducer of Nerve Growth Factor in articular cartilage via the ALK5-Smad2/3 pathway. Potential role in OA related pain? Osteoarthritis Cartilage. 2015; 23(3):478-86. doi:10.1016/j.joca.2014.12.005; Lantero A, Tramullas M, Diaz A, Hurle MA. Transforming growth factor-β in normal nociceptive processing and pathological pain models. Mol Neurobiol. 2012;45(1):76-86. doi:10.1007/s12035-011-8221-1; Echeverry S, Shi XQ, Haw A, et al. Transforming growth factor-beta1 impairs neuropathic pain through pleiotropic effects. Mol Pain. 2009;5:16. doi:10.1186/1744-8069-5-16; Christiansen BA, Bhatti S, Goudarzi R, Emami S. Management of Osteoarthritis with Avocado/Soybean Unsaponifiables. Cartilage. 2015;6(1):30-44. doi:10.1177/1947603514554992; Tramullas M, Lantero A, Diaz A, et al. BAMBI (bone morphogenetic protein and activin membrane-bound inhibitor) reveals the involvement of the transforming growth factor-beta family in pain modulation. J Neurosci. 2010;30(4):1502-01. doi:10.1523/JNEUROSCI.2584-09.2010; Mapp PI, Walsh DA. Mechanisms and targets of angiogenesis and nerve growth in osteoarthritis. Nat Rev Rheumatol. 2012; 8(7):390-8. doi:10.1038/nrrheum.2012.80; Brown RA, Weiss JB. Neovascularisation and its role in the osteoarthritic process. Ann Rheum Dis. 1988;47(11):881-5. doi:10.1136/ard.47.11.881; Bonnet CS, Walsh DA. Osteoarthritis, angiogenesis and inflammation. Rheumatology (Oxford). 2005;44(1):7-16. doi:10.1093/ rheumatology/keh344; Ashraf S, Wibberley H, Mapp PI, et al. Increased vascular penetration and nerve growth in the meniscus: a potential source of pain in osteoarthritis. Ann Rheum Dis. 2011; 70(3):523-9. doi:10.1136/ard.2010.137844; Walker GD, Fischer M, Gannon J, et al. Expression of type-X collagen in osteoarthritis. J Orthop Res. 1995;13(1):4-12. doi:10.1002/jor.1100130104; Ballara SC, Miotla JM, Paleolog EM. New vessels, new approaches: angiogenesis as a therapeutic target in musculoskeletal disorders. Int J Exp Pathol. 1999;80(5):235-50. doi:10.1046/j.1365-2613.1999.00129.x; Kolostova K, Taltynov O, Pinterova D, et al. Tissue repair driven by two different mechanisms of growth factor plasmids VEGF and NGF in mice auricular cartilage: regeneration mediated by administering growth factor plasmids. Eur Arch Otorhinolaryngol. 2012;269(7):1763-70. doi:10.1007/s00405-011-1821-6; Tchetina EV, Poole AR, Zaitseva EM, et al. Differences in mTOR (mammalian target of rapamycin) gene expression in the peripheral blood and articular cartilages of osteoarthritic patients and disease activity. Arthritis. 2013;2013:461486. doi:10.1155/2013/461486; Четина ЕВ, Братыгина ЕА, Зайцева ЕМ и др. Прогнозирование течения остеоартроза по экспрессии гена mTOR (mammalian target of rapamycin). Научно-практическая ревматология. 2012;50(1):27-32. doi:10.14412/1995-4484-2012-500 [Chetina EV, Bratygina EA, Zaitseva EM, et al. Prediction of the course of osteoarthrosis from mTOR (mammalian target of rapamycin) gene expression. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2012;50(1):27-32. doi:10.14412/1995-4484-2012-500 (In Russ.)].; Четина ЕВ, Маркова ГА, Таскина ЕА и др. Молекулярные механизмы регуляции боли у больных остеоартрозом. Научно-практическая ревматология. 2016; 54(4):424-31. doi:10.14412/1995-4484-2016-424-431 [Chetina EV, Markova GA, Taskina EA, et al. Molecular mechanisms for pain regulation in patients with osteoarthritis. NauchnoPrakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(4):424-31. doi:10.14412/1995-4484-2016-424-431 (In Russ.)].; Wolfe F, Michaud K. Severe rheumatoid arthritis (RA), worse outcomes, comorbid illness, and sociodemographic disadvantage characterize RA patients with fibromyalgia. J Rheumatol. 2004;31(4):695-700.; Andersson ML, Svensson B, Bergman S. Chronic widespread pain in patients with rheumatoid arthritis and the relation between pain and disease activity measures over the first 5 years. J Rheumatol. 2013;40(12): 1977-85. doi:10.3899/jrheum.130493; Rifbjerg-Madsen S, Christensen AW, Boesen M, et al. Can the painDETECT Questionnaire score and MRI help predict treatment outcome in rheumatoid arthritis: protocol for the Frederiksberg hospital's Rheumatoid Arthritis, pain assessment and Medical Evaluation (FRAME-cohort) study. BMJ Open. 2014;4(11):e006058. doi:10.1136/bmjopen-2014-006058; Tchetina EV, Pivanova AN, Markova GA, et al. Rituximab down-regulates gene expression associated with cell proliferation, survival, and proteolysis in the peripheral blood from rheumatoid arthritis patients: a link between high baseline autophagy-related ULK1 expression and improved pain control. Arthritis. 2016;2016:4963950. doi:10.1155/2016/4963950; Orhan CE, Onal A, Ulker S. Antihyperalgesic and antiallodynic effect of sirolimus in neuropathic pain and the role of cytokines in this effect. Neurosci Lett. 2010;481(1):17-20. doi:10.1016/j.neulet.2010.06.039; Yan H, Zhou HF, Hu Y, Pham CT. Suppression of experimental arthritis through AMP-activated protein kinase activation and autophagy modulation. J Rheum Dis Treat. 2015;1(1):5. doi:10.23937/2469-5726/1510005; Kurtz S, Ong K, Lau E, et al. Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to 2030. J Bone Joint Surg Am. 2007; 89(4):780-5. doi:10.2106/JBJS.F.00222; Lim AYN, Doherty M. What of guidelines for osteoarthritis? Rheum Dis. 2011; 14:136-44. doi:10.1111/j.1756-185X.2011.01609.x; Hilton ME, Gioe T, Noorbaloochi S, Singh JA. Increasing comorbidity is associated with worsening physical function and pain after primary total knee arthroplasty. BMC Musculoskelet Disord. 2016;17(1):421. doi:10.1186/s12891-016-1261-y; Liu SS, Buvanendran A, Rathmell JP, et al. Predictors for moderate to severe acute postoperative pain after total hip and knee replacement. Int Orthop. 2012;36(11):2261-7. doi:10.1007/s00264-012-1623-5; Judge A, Arden NK, Cooper C, et al. Predictors of outcomes of total knee replacement surgery. Rheumatology (Oxford). 2012;51: 1804-13. doi:10.1093/rheumatology/kes075; Wylde V, Dixon S, Blom AW. The role of preoperative self-efficacy in predicting outcome after total knee replacement. Musculoskeletal Care. 2012;10(2):110-8. doi:10.1002/msc.1008; Petersen KK, Arendt-Nielsen L, Simonsen O, et al. Presurgical assessment of temporal summation of pain predicts the development of chronic postoperative pain 12 months after total knee replacement. Pain. 2015;156(1):55-61. doi:10.1016/j.pain.0000000000000022; Granot M, Lowenstein L, Yarnitsky D, et al. Postcesarean section pain prediction by preoperative experimental pain assessment. Anesthesiology. 2003;98:1422-6. doi:10.1097/00000542-200306000-00018; Edwards RR, Mensing G, Cahalan C, et al. Alteration in pain modulation in women with persistent pain after lumpectomy: influence of catastrophizing. J Pain Symptom Manage. 2013;46:30-42. doi:10.1016/j.jpainsymman.2012.06.016; Yarnitsky D, Crispel Y, Eisenberg E, et al. Prediction of chronic post-operative pain: preoperative DNIC testing identifies patients at risk. Pain. 2008;138:22-8. doi:10.1016/j.pain.2007.10.033; Ji RR, Xu ZZ, Gao YJ. Emerging targets in neuroinflammation-driven chronic pain. Nat Rev Drug Discov. 2014;13(7):533-48. doi:10.1038/nrd4334; Pearle A, Scanzello C, George S, et al. Elevated high-sensitivity C-reactive protein levels are associated with local inflammatory findings in patients with osteoarthritis. Osteoarthr Cartilage. 2007;15:516-23. doi:10.1016/j.joca.2006.10.010; Gandhi R, Santone D, Takahashi M, et al. Inflammatory predictors of ongoing pain 2 years following knee replacement surgery. Knee. 2013;20(5):316-8. doi:10.1016/j.knee.2012.10.015; Clark AK, Yip PK, Grist J, et al. Inhibition of spinal microglial cathepsin S for the reversal of neuropathic pain. Proc Natl Acad Sci U S A. 2007;104(25):10655-60. doi:10.1073/pnas.0610811104; Clark AK, Yip PK, Malcangio M. The liberation of fractalkine in the dorsal horn requires microglial cathepsin S. J Neurosci. 2009;29(21):6945-54. doi:10.1523/ JNEUROSCI.0828-09.2009; Berta T, Park CK, Xu ZZ, et al. Extracellular caspase-6 drives murine inflammatory pain via microglial TNF-alpha secretion. J Clin Invest. 2014;124(3):1173-86. doi:10.1172/JCI72230; Gardner J, Borgmann K, Deshpande MS, et al. Potential mechanisms for astrocyteTIMP-1 downregulation in chronic inflammatory diseases. J Neurosci Res. 2006;83(7): 1281-92. doi:10.1002/jnr.20823; Tchetina EV, Makarov SA, Kuzin AN. Coordinated expression of the genes associated with cell growth (mTOR), collagen degradation (cathepsin K), and lipid metabolism (fatty acid synthase) in the peripheral blood and articular cartilage of the end-stage osteoarthritic patients. Ann Rheum Dis. 2013;72(3):694. doi:10.1136/annrheumdis2013-eular.2051; Tchetina EV, Glemba KE, Markova GA, Makarov SA. Identification of postoperative pain biomarkers using gene expression analyses in the peripheral blood of osteoarthritic patients prior to joint replacement. Ann Rheum Dis. 2019;78(2):A520. doi:10.1136/annrheumdis-2019-eular.5313; https://mrj.ima-press.net/mrj/article/view/999

الاتاحة: https://mrj.ima-press.net/mrj/article/view/999
https://doi.org/10.14412/1996-7012-2020-1-93-100

المؤلفون: E. V. Chetina, E. P. Sharapova, N. G. Kashevarova, E. A. Taskina, G. A. Markova, L. I. Alekseeva, A. A. Lila, Е. В. Четина, Е. П. Шарапова, Н. Г. Кашеварова, Е. А. Таскина, Г. А. Маркова, Л. И. Алексеева, А. М. Лила

المصدر: Modern Rheumatology Journal; Том 13, № 1 (2019); 64-70 ; Современная ревматология; Том 13, № 1 (2019); 64-70 ; 2310-158X ; 1996-7012 ; 10.14412/1996-7012-2019-1

مصطلحات موضوعية: кровь, diabetes mellitus, gene expression, energy metabolism, blood, сахарный диабет, экспрессия генов, энергетический метаболизм

وصف الملف: application/pdf

Relation: https://mrj.ima-press.net/mrj/article/view/888/852; Courties A, Sellam J. Osteoarthritis and type 2 diabetes mellitus: What are the links? Diabetes Res Clin Pract. 2016 Dec;122: 198-206. doi:10.1016/j.diabres.2016.10.021. Epub 2016 Nov 5.; Bijlsma JW, Berenbaum F, Lafeber FP. Osteoarthritis: an update with relevance for clinical practice. Lancet. 2011 Jun 18;377(9783):2115-26. doi:10.1016/S0140-6736(11)60243-2.; Felson DT. Clinical practice. Osteoarthritis of the knee. N Engl J Med. 2006 Feb 23; 354(8):841-8.; Zullig LL, Bosworth HB, Jeffreys AS, et al. The association of comorbid conditions with patient-reported outcomes in Veterans with hip and knee osteoarthritis. Clin Rheumatol. 2015 Aug;34(8):1435-41. doi:10.1007/s10067-014-2707-y. Epub 2014 Jun 12.; Parkinson L, Waters DL, Franck L. Systematic review of the impact of osteoarthritis on health outcomes for comorbid disease in older people. Osteoarthritis Cartilage. 2017 Nov;25(11):1751-1770. doi:10.1016/jjoca.2017.07.008. Epub 2017 Jul 11.; Singh JA, Lewallen DG. Time trends in the characteristics of patients undergoing primary total knee arthroplasty. Arthritis Care Res (Hoboken). 2014 Jun;66(6):897-906. doi:10.1002/acr.22233.; Berenbaum F, Griffin TM, Liu-Bryan R. Metabolic Regulation of Inflammation in Osteoarthritis. Arthritis Rheumatol. 2017 Jan; 69(1):9-21. doi:10.1002/art.39842.; Tchetina EV, Markova GA, Poole AR, et al. Deferoxamine suppresses collagen cleavage, protease, cytokine, COL10A1 expression and upregulates AMPK and Krebs cycle genes in human osteoarthritic cartilage. Int J Rheumatol. 2016;2016:6432867. doi:10.1155/2016/6432867. Epub 2016 Nov 30.; Tchetina EV, Poole AR, Zaitseva EM, et al. Differences in mTOR (mammalian target of rapamycin) gene expression in the peripheral blood and articular cartilages of osteoarthritic patients and disease activity. Arthritis. 2013; 2013:461486. doi:10.1155/2013/461486. Epub 2013 Jun 25.; Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. (2011) Nat. Rev. Mol. Cell. Biol. 2011; 12(1):21-35. doi:10.1038/nrm3025.; Jeon SM. Regulation and function of AMPK in physiology and diseases. Exp Mol Med. 2016 Jul 15;48(7):e245. doi:10.1038/emm.2016.81.; Xiao H, Gu Z, Wang G, et al. The possible mechanisms underlying the impairment of HIF-1a pathway signaling in hyperglycemia and the beneficial effects of certain therapies. Int JMed Sci. 2013 Aug 22;10(10):1412-21. doi:10.7150/ijms.5630.eCollection 2013.; Kim J. Regulation of Immune Cell Functions by Metabolic Reprogramming. J Immunol Res. 2018 Feb 13;2018: 8605471. doi:10.1155/2018/8605471.eCollection 2018.; Yang Z, Matteson EL, Goronzy JJ, et al. T-cell metabolism in autoimmune disease. Arthritis Res Ther. 2015 Feb 11;17:29. doi:10.1186/s13075-015-0542-4.; Herbel C, Patsoukis N, Bardhan K, et al. Clinical significance of T cell metabolic reprogramming in cancer. Clin Transl Med. 2016 Dec;5(1):29. doi:10.1186/s40169-016-0110-9. Epub 2016 Aug 10.; Marshall S. Role of insulin, adipocyte hormones, and nutrient-sensing pathways in regulating fuel metabolism and energy homeostasis: a nutritional perspective of diabetes, obesity, and cancer. Sci STKE. 2006 Aug 1; 2006(346):re7.; Четина ЕВ, ДиБатиста Д, Пул АР. Роль простагландина E2 в ингибировании разрушения коллагена суставного хряща больных остеоартрозом. Научно-практическая pевматоло™я. 2009;47(3):18-24. doi:10.14412/1995-4484-2009-1308; Straub RH, Cutolo M, Buttgereit F, et al. Energy regulation and neuroendocrine-immune control in chronic inflammatory diseases. J Intern Med. 2010 Jun;267(6):543-60. doi:10.1111/j.1365-2796.2010.02218.x. Epub 2010 Jan 28.; Vallon V, Komers R. Pathophysiology of the diabetic kidney. Compr Physiol. 2011 Jul; 1(3):1175-232. doi:10.1002/cphy.c100049.; Ширинский ВС, Ширинский ИВ. Коморбидные заболевания — актуальная проблема клинической медицины. Сибирский медицинский журнал. 2014;29(1): 7-12.; Ленинджер А. Основы биохимии. Москва: Мир; 1985. 367 c.; https://mrj.ima-press.net/mrj/article/view/888

الاتاحة: https://mrj.ima-press.net/mrj/article/view/888
https://doi.org/10.14412/1996-7012-2019-1-64-70

المؤلفون: L. I. Alekseeva, E. A. Taskina, N. G. Kashevarova, E. P. Sharapova, S. G. Anikin, E. A. Strebkova, T. А. Korotkova, T. A. Raskina, E. V. Zonova, E. N. Otteva, Л. И. Алексеева, Е. А. Таскина, Н. Г. Кашеварова, Е. П. Шарапова, С. Г. Аникин, Е. А. Стребкова, Т. А. Короткова, Т. А. Раскина, Е. В. Зонова, Э. Н. Оттева

المصدر: Rheumatology Science and Practice; Vol 56, No 2 (2018); 157-163 ; Научно-практическая ревматология; Vol 56, No 2 (2018); 157-163 ; 1995-4492 ; 1995-4484 ; 10.14412/rsp20182

مصطلحات موضوعية: диацереин, metabolic syndrome, treatment, diacerein, метаболический синдром, лечение

وصف الملف: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/2520/1675; Allen KD, Choong PF, Davis AM, et al. OA: Models for appropriate care across the disease continuum. Best Pract Res Clin Rheumatol.2016 Jun;30(3):503-35. doi:10.1016/j.berh.2016.09.003; World Health Organization: Obesity and overweight. Fact Sheet No.311. accessed on November 20, 2012. 2013. Mar. Available from: http://www.who.int/mediacentre/factsheets/fs311/en/; World Health Organization. Obesity: Preventing And Managing The Global Epidemic. Geneva: WHO; 1997.; Blagojevic M, Jinks C, Jeffery A, Jordan KP. Risk factors for onset of osteoarthritis of the knee in older adults: A systematic review and meta-analysis. Osteoarthritis Cartilage. 2010 Jan;18(1):24-33. doi:10.1016/J.Joca.2009.08.010; Fu Y, Griffin TM. Obesity, osteoarthritis and aging: The biomechanical links. Mechanobiology of obesity and related diseases. Springer International Publishing; 2015. P. 181-201.; Кашеварова НГ, Алексеева ЛИ, Таскина ЕА, Смирнов АВ. Ведущие факторы прогрессирования остеоартрита коленных суставов. Влияние симптоматических препаратов замедленного действия на течение заболевания (5-летнее проспективное исследование). Фарматека. 2017;7(340):40-5.; Jiang L, Tian W, Wang Y, et al. Body mass index and susceptibility to knee osteoarthritis: a systematic review and meta-analysi. Joint Bone Spine. 2012 May;79(3):291-7. doi:10.1016/j.jbspin.2011.05.015; Wang Y, Simpson JA, Wluka AE, et al. Relationship between body adiposity measures and risk of primary knee and hip replacement for osteoarthritis: a prospective cohort study. Arthritis Res Ther. 2009;11(2):R31. doi:10.1186/ar2636; McNulty AL, Miller MR, O'Connor SK, Guilak F. The effects of adipokines on cartilage and meniscus catabolism. Connect Tissue Res. 2011;52(6):523-33. doi:10.3109/03008207.2011.597902; Hanefeld M, Schaper F, Ceriello A. Geschichte Und Definition(En) Des Metabolischen Syndroms. Internist. 2007;48:117-25. doi:10.1007/s00108-006-1786-5; Диагностика илечение метаболического синдрома. Вкн.: Сборник национальных клинических рекомендаций. Москва: Силицея-Полиграф; 2009. С. 106-43.; Wang H, Cheng Y, Shao D, et аl. Metabolic syndrome increases the risk for knee osteoarthritis: A meta-analysis. Evid Based Complement Alternat Med. 2016;2016:7242478. doi:10.1155/2016/7242478; Shin D. Association between metabolic syndrome, radiographic knee osteoarthritis, and intensity of knee pain: Results of a national survey. J Clin Endocrinol Metab. 2014 Sep;99(9):3177-83. doi:10.1210/jc.2014-1043; Velasquez MT, Katz JD. Osteoarthritis: Another component of metabolic syndrome? Metab Syndr Relat Disord. 2010 Aug;8(4):295-305. doi:10.1089/met.2009.0110; Yoshimura N, Muraki S, Oka H, et al. Accumulation of metabolic risk factors such as overweight, hypertension, dyslipidaemia, and impaired glucose tolerance raises the risk of occurrence and progression of knee osteoarthritis: A 3-year follow-up of the road study. Osteoarthritis Cartilage. 2012 Nov;20 (11):1217-26. doi:10.1016/j.joca.2012.06.006; Yoshimura N, Muraki S, Oka H, et al. Association of knee osteoarthritis with the accumulation of metabolic risk factors such as overweight, hypertension, dyslipidemia, and impaired glucose tolerance in japanese men and women: The road study. J Rheumatol. 2011;38(5):921-30. doi:10.3899/Jrheum.100569; Abourazzak F, Talbi S, Lazrak F, et al. Does metabolic syndrome or its individual components affect pain and function in knee osteoarthritis women? Curr Rheumatol Rev. 2015 May 21. doi:10.2174/1573397111666150522093337; Chadha R. Revealed aspect of metabolic osteoarthritis. J Orthop. 2016 Jul 9;13(4):347-51. doi:10.1016/j.jor.2016.06.029.eCollection 2016 Dec.; Farnaghi S, Crawford R, Xiao Y, Prasadam I. Cholesterol metabolism in pathogenesis of osteoarthritis disease. Int J Rheum Dis. 2017 Feb;20(2):131-40. doi:10.1111/1756-185X.13061; Martel-Pelletier J, Pelletier JP. Effects of diacerein at the molecular level in the osteoarthritis disease process. Ther Adv Musculoskelet Dis.2010 Apr;2(2):95-104. doi:10.1177/1759720X09359104; Steinecker-Frohnwieser B, Kaltenegger H, Weigl L, et al. Pharmacological treatment with diacerein combined with mechanical stimulation affects the expression of growth factors in human chondrocytes. Biochem Biophys Rep. 2017 Jul 1;11:154-60. doi:10.1016/j.bbrep.2017.06.006; Sun H, Luo G, Chen D, Xiang Z. A comprehensive and system review for the pharmacological mechanism of action of rhein, an active anthraquinone ingredient. Front Pharmacol. 2016 Aug 17;7:247. doi:10.3389/fphar.2016.00247. eCollection 2016.; Zhou YX, Xia W, Yue W, et al. Rhein: A review of pharmacological activities. Evid Based Complement Alternat Med. 2015;2015:578107. doi:10.1155/2015/578107; Наумов АВ, Ховасова НО. Рекомендованная терапия остеоартрита: новые решения старых задач. Русский медицинский журнал. 2016;24(3):197-202 [Naumov AV, Khovasova NO. Recommended osteoarthritis therapy: new solutions to old problems. Russkii Meditsinskii Zhurnal. 2016;24(3):197-202 (In Russ.)].; Jatwa R, Kar A.Anti-inflammatory and anti-peroxidative roles of diacerein are possibly mediated through an alteration in thyroid functions in animal model of inflammation. Fundament Clin Pharmacol. 2009;23(4):465-71. doi:10.1111/j.1472-8206.2009.00685.x; Алексеева ЛИ, Кашеварова НГ, Таскина ЕА идр. Эффективность ибезопасность диацереина упациентов состеоартритом коленных суставов. Современная ревматология. 2017;11(3):50-7. doi: 10/14412/1996-7012-2017-3-50-57; Шарапова ЕП, Кашеварова НГ, Зайцева ЕМ и др. Оценка эффективности и безопасности диацереина у пациентов с остеоартрозом тазобедренных суставов. Медицинский совет. 2017;(1s):84-9.; Каратеев АЕ, Алексеева ЛИ, Цурган АВ, Гонтаренко НВ. Оценка эффективности и безопасности комплексной терапии скелетно-мышечной боли с использованием Диацереина (по данным исследования РОКАДА – ретроспективная оценка клинических аспектов применения диафлекса при остеоартрозе). Неврология и ревматология. Приложение к журналу Consilium Medicum. 2016;(2):26-32.; Pavelka K, Bruyere O, Cooper C, et al. Diacerein: benefits, risks and place in the management of osteoarthritis. An opinion-based report from the ESCEO. Drugs Aging. 2016;33(2):75-85. doi:10.1007/s40266-016-0347-4; Li H, George DM, Jaarsma RL, Mao X. Metabolic syndrome and components exacerbate osteoarthritis symptoms of pain, depression and reduced knee function. Ann Transl Med. 2016 Apr;4(7):133. doi:10.21037/atm.2016.03.48; Tootsi K, Mаrtson A, Kals J, et al. Metabolic factors and oxidative stress in osteoarthritis: a case-control study. Scand J Clin Lab Invest. 2017 Jul 24:1-7. doi:10.1080/00365513.2017.1354255; Yasuda E, Nakamura R, Matsugi R, et al. Association between the severity of symptomatic knee osteoarthritis and cumulative metabolic factors. Aging Clin Exp Res. 2017 Jul 31. doi:10.1007/s40520-017-0808-6; Baudart P, Louati K, Marcelli C, et al. Association between osteoarthritis and dyslipidaemia: a systematic literature review and meta-analysis. RMD Open. 2017;3:e000442. doi:10.1136/ rmdopen-2017-000442; Du H, Shao J, Gu P, et al. Improvement of glucose tolerance by rhein with restored early-phase insulin secretion in db/db mice. J Endocrinol Invest 2012;35:607-12. doi:10.1007/BF03345796; Liu J, Chen Z, Zhang Y, et al. Rhein protects pancreatic B-cells from dynamin-related protein-1-mediated mitochondrial fission and cell apoptosis under hyperglycemia. Diabetes. 2013;62:3927-393. doi:10.2337/db13-0251; Tobar N, Oliveira AG, Guadagnini D, et al. Diacerhein improves glucose tolerance and insulin sensitivity in mice on a high-fat diet. Endocrinology. 2011;152:4080-93. doi:10.1210/en.2011-0249; Malaguti C, Vilella CA, Vieira KP, et al. Diacerhein downregulate proinflammatory cytokines expression and decrease the autoimmune diabetes frequency in nonobese diabetic (NOD) mice. Int Immunopharmacol.2008;8:782-91. doi:10.1016/j.intimp.2008.01.020; Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006;444:860-7. doi:10.1038/nature05485; Ramos-Zavala MG, Gonzalez-Ortiz M, Martinez-Abundis E, et al. Effect of diacerein on insulin secretion and metabolic control in drug-naive patients with type 2 diabetes: a randomized clinical trial. Diabetes Care.2011 Jul;34(7):1591-4. doi:10.2337/dc11-0357; Villar MM, Martinez-Abundis E, Preciado-Mаrquez RO, Gonzalez-Ortiz M. Effect of diacerein as an add-on to metformin in patients with type 2 diabetes mellitus and inadequate glycemic control. Arch Endocrinol Metab. 2017 Mar-Apr;61(2):188-92. doi:10.1590/2359-3997000000242; Cardoso CRL, Leite NC, Carlos FO, et al. Efficacy and safety of diacerein in patients with inadequately controlled type 2 diabetes: A randomized controlled trial. Diabetes Care. 2017 Aug;dc170374. doi:10.2337/dc17-0374; Sheng X, Wang M, Lu M, et al. Rhein ameliorates fatty liver disease through negative energy balance, hepatic lipogenic regulation, and immunomodulation in diet-induced obese mice. Am J Physiol Endocrinol Metab. 2011;300:886-93. doi:10.1152/ajpendo.00332.2010; Lin YJ, Hu G, Li KJ, et al. The protection of rhein lysinate to liver in diabetic mice induced by high-fat diet and streptozotocin. Arch Pharm Res. 2015;38:885-92. doi:10.1007/s12272-014-0423-4; Guo MZ, Li XS, Xu HR, et al. Rhein inhibits liver fibrosis induced by carbon tetrachloride in rats. Acta Pharmacol Sinica. 2002;23(8):739-44.; https://rsp.mediar-press.net/rsp/article/view/2520

الاتاحة: https://rsp.mediar-press.net/rsp/article/view/2520
https://doi.org/10.14412/1995-4484-2018-157-163

المؤلفون: L. I. Alekseeva, E. P. Sharapova, N. G. Kashevarova, E. A. Taskina, A. M. Lila, A. N. Bogdanov, S. A. Bozhkova, A. A. Bagretsova, S. M. Noskov, E. A. Grunina, Л. И. Алексеева, Е. П. Шарапова, Н. Г. Кашеварова, Е. А. Таскина, А. М. Лила, А. Н. Богданов, С. А. Божкова, А. А. Багрецова, С. М. Носков, Е. А. Грунина

المصدر: Modern Rheumatology Journal; Том 12, № 2 (2018); 44-49 ; Современная ревматология; Том 12, № 2 (2018); 44-49 ; 2310-158X ; 1996-7012 ; 10.14412/1996-7012-2018-2

مصطلحات موضوعية: нежелательные явления, Chondroguard, intra-articular injection, efficacy, safety, adverse events, хондрогард, внутрисуставное введение, эффективность, безопасность

وصف الملف: application/pdf

Relation: https://mrj.ima-press.net/mrj/article/view/824/793; Arden N, Nevit MC. Osteoarthritis: Epidemiology. Best Pract Res Clin Rheumatol. 2006 Feb;20(1):3-25.; Галушко ЕА. Медико-социальная значимость ревматических заболеваний. Автореф. дисс. докт. мед. наук. Москва; 2011. [Galushko EA. Medical and social significance of rheumatic diseases. Autoref. diss. doct. med. sci. Moscow; 2011.]; Sangha O. Epidemiology of rheumatic disease. Rheumatology (Oxford). 2000 Dec;39 Suppl 2:3-12.; Laurent TC, Laurent UB, Fraser JR. The structure and function of hyaluronan: An overview. Immunol Cell Biol. 1996 Apr;74(2):A1-7.; Bland JH, Cooper SM. Osteoarthritis: a review of the cell biology involved and evidence for reversibility. Management rationally related to known genesis and pathophysiology. Semin Arthritis Rheum. 1984 Nov;14(2): 106-33.; Ward PD, Thibeault SL, Gray SD. Hyaluronic acid: its role in voce. J Voice. 2002 Sep;16(3):303-9.; Стребкова ЕА, Соловьева ИВ, Шарапова ЕП и др. Оценка эффективности медикаментозной и немедикаментозной терапии ожирения у больных остеоартрозом коленных суставов. Тезисы VI Съезда ревматологов России. Москва; 2013. С. 152-3. [Strebkova EA, Solov'eva IV, Sharapova EP, et al. Evaluation of the effectiveness of drug and non-drug therapy of obesity in patients with osteoarthritis of the knee. Tezisy VI S"ezda revmatologov Rossii. Moscow; 2013. P. 152-3.]; Goldriring MB. The role of the chondrocyte in osteoarthritis. Arthritis Rheum. 2000 Sep;43(9):1916-26.; Alaaeddine N, Olee T, Hashimoto S, et al. Production of the chemokine RANTES by articular chondrocytes and role in cartilage degradation. Arthritis Rheum. 2001 Jul;44(7): 1633-43.; Ronca F, Palmieri L, Panicucci P, Ronca G. Anti-inflammatory activity of chondroitin sulfate. Osteoarthritis Cartilage. 1998 May;6 Suppl A:14-21.; Calamia V, Mateos J, Fernandez-Puente P, et al. A pharmacoproteomic study confirms the synergistic effect of chondroitin sulfate and glucosamine. Sci Rep. 2014 Jun 10;4: 5069. doi:10.1038/srep05069.; Lambert C, Mathy-Hartert M, Dubuc JE, et al. Characterization of synovial angiogenesis in osteoarthritis patients and its modulation by chondroitin sulfate. Arthritis Res Ther. 2012 Mar 12;14(2):R58. doi:10.1186/ar3771.; Tat SK, Pelletier JP, Verges J, et al. Chondroitin and glucosamine sulfate in combination decrease the pro-resorptive properties of human osteoarthritis subchondral bone osteoblasts: a basic science study. Arthritis Res Ther. 2007;9(6):R117.; Leeb BF, Schweitzer H, Montag K, Smolen JS. A meta-analysis of chondroitin sulfate in the treatment of osteoarthritis. Osteoarthritis Cartilage. 1999;7(Suppl A):130.; Eugenio-Sarmiento RM, Vanapat DH, Salido EJ. The efficacy of chondroitinsulfate in the treatment of knee osteoarthritis: a meta-analysis. Osteoarthritis Cartilage. 1999;7(Suppl A):139.; Schneider H. Sympptom-Modifying Effect of Chondroitin Sulfate in Knee Osteoarthritis: A Meta-Analysis of Randomized Placebo-Controlled Trials Performed with Structum. Open Rheumatol J. 2012;6:183-9. doi:10.2174/187431290 1206010183. Epub 2012 Jul 25.; Singh JA, Noorbaloochi S, MacDonald R, Maxwell LJ. Chondroitin for osteoarthritis (Rewiew). Cochrane Database Syst Rev. 2015 Jan 28;1:CD005614. doi:10.1002/14651858. CD005614.pub2.; Henrotin Y, Marty M, Mobasheri A. What is the current status of chondroitin sulfate and glucosamine for the treatment of knee osteoarthritis? Maturitas. 2014 Jul; 78(3):184-7. doi:10.1016/j.maturitas. 2014.04.015. Epub 2014 May 1.; Lee YH. Chondroitin sulfate is superior to placebo in symptomatic kneeosteoarthritis. Ann Rheum Dis. 2017 Oct 9. pii: annrheumdis2017-212452. doi:10.1136/annrheumdis2017-212452. [Epub ahead of print].; Алексеева ЛИ, Архангельская ГС, Давыдова АФ и др. Отдаленные результаты применения структума (по материалам многоцентрового исследования). Терапевтический архив. 2003;(9):82-6. [Alekseeva LI, Arkhangel'skaya GS, Davydova AF, et al. Long-term results of the use of structum (on materials of a multicenter study). Terapevticheskii arkhiv. 2003;(9):82-6. (In Russ.)].; Алексеева ЛИ, Аникин СГ, Шарапова ЕП и др. Исследование эффективности, переносимости и безопасности препарата Хондрогард у пациентов с остеоартрозом. Русский медицинский журнал. 2013;(32):1624-7. [Alekseeva LI, Anikin SG, Sharapova EP, et al. Study of the efficacy, tolerance and safety of Chondrogard in patients with osteoarthritis. Russkii meditsinskii zhurnal. 2013;(32):1624-7. (In Russ.)].; Шарапова ЕП, Алексеева ЛИ, Кашеварова НГ и др. Оценка эффективности, переносимости и безопасности хондрогарда у больных остеоартрозом коленных суставов и коморбидностью. Научно-практическая ревматология. 2017;55(Прил 1); 138. [Sharapova EP, Alekseeva LI, Kashevarova NG, et al. Evaluation of the effectiveness, tolerability and safety chondrogard in patients with osteoarthritis of the knee joints and comorbidity. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2017;55(Suppl 1);138.]; https://mrj.ima-press.net/mrj/article/view/824

الاتاحة: https://mrj.ima-press.net/mrj/article/view/824
https://doi.org/10.14412/1996-7012-2018-2-44-49

المؤلفون: E. P. Sharapova, N. G. Kashevarova, E. M. Zaytseva, S. G. Anikin, T. A. Korotkova, L. I. L.I. Alexeeva, Е. П. Шарапова, Н. Г. Кашеварова, Е. М. Зайцева, С. Г. Аникин, Т. А. Короткова, Л. И. Алексеева

المصدر: Meditsinskiy sovet = Medical Council; № 1S (2017); 84-89 ; Медицинский Совет; № 1S (2017); 84-89 ; 2658-5790 ; 2079-701X ; 10.21518/2079-701X-2017-1

مصطلحات موضوعية: нежелательные явления, Diacerein, clinical efficacy, tolerability, adverse events, болевой синдром, диацереин, клиническая эффективность, переносимость

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/1666/1605; Галушко Е.А. Медико-социальная значимость ревматических заболеваний: автореф. дис. .; д-ра мед. наук. М., 2011.; Sangha O. Epidemiology of rheumatic disease. Rheumatology, 2000, 39(Suppl.2): 3-12.; Hardingham TE, Fosang AJ, Dubhia J. The structure, function and turnover of aggrecan, the large aggregating proteoglycan from cartilage. Aur J Clin Chem Clin Biochem, 1994, 32: 249-57.; Bijlsma JW, Borenbaum F, Lafeber FP. Osteoarthritis: an update with relevance for clinical practice. Lancet, 2011, 377(9783): 2115-26. DOI:10.1016/S0140–6736(11)60243–2.; Sellam J, Berenbaum F. The role of synovitis; in pathophysiology and clinical symtoms of osteoarthritis. Nat rev Rheumatol, 2010, 6(11): 625-35. DOI:10.1038/nrrheum.2010.159. Epub 2010 Oct 5.; Boureau F, Schneid H et al. The IPSO study: ibuprofen, paracetamol study in osteoarthritis. A randomized comparative clinical study comparing the efficacy and safety of ibuprofen and paracetamol analgesic treatment of osteoarthritis of knee or hip. Ann. Rheum. Dis., 2004, 63: 1028-1035.; Zhang W, Jones A, Doherty M. Does paracetamol (acetaminophen) reduce pain of osteoarthritis? A meta-analysis of randomized controlled trials. Ann. Rheum. Dis., 2004, 63: 901-907.; Cappell MS, Schein JR. Diagnosis and treatment of nonsteroidal anti-inflametory drug-associated upper gastrointestinal toxicity. Gastrointerol. Clin. N. Am., 2000, 29: 97-124.; Tenenbaum О. The epidemiology of nonsteroidal anti-inflametory drugs. Can. J. Gastrointerol., 1999, 13: 119-122.; Van de Loo FA, Joosten LA, van Lent PL et al. Role of interleukin-1, tumor necrosis factor alfa, and interleukin-6 in cartilage proteoglycan metabolism and destruction: effect of in situ blocking in murine antigen-and zymosan – induced arthritis. Arth. Rheum., 1995, 38(2): 164-72.; Pelletier JP, Mineau F, Boileau C et al. Diacerhein reduce the level of cartilage chondrocyte DNA fragmentation and death in experimental dog osteoarthritis cartilage atthe same time that in inhibits caspase-3 and inducible nitric oxide synthase. Clin Exp Rheumatol, 2003, 21(2): 171-7.; Martel-Pelletier J, Mineau F and Pelleier JP. In vitro effects of diacerhein and rhein on IL-1 andTNF-alpha systems in human osteoarthritis tissues. J Rheumatol, 1998, 25: 753-762.; Mazieres B, Berdah L, Thiechart M.) Diacetyl rhein administration model of experimental osteoarthritis in the rabbit. Rev Rhum Ed Fr, 1993, 60: 77S-81S.; Tamura T and Ohmori K. Rhein, an active metabolite of diacerhein, suppresses the interleukin-1 alpha-induced proteoglycan degradation in cultured rabbit articular chondrocytes. Jpn J Pharmacol, 2001, 85: 101-104.; Pavelka K, Trc T, Karpas K еt al. The efficacy and safety of Diacerhein in the treatmen of painful knee osteoarthritis: a randomised, , double-blind, place-bocontrolled multicentre study. Poster presented at: The Annual Evropean Congress of Rheuma tology, EULAR; June 8-11, 2005. Vienna, Austria.; Rintelen B, Neumann K, Leeb BF. A meta-analysis of controlled clinical studies with diacerhein in the treatment osteoarthritis. Arch Int Med, 2006, 166(17): 1899-906.; Bendele AN, Bendele RA, Hulman JF, Swann BP. Benefical effects of treatment with diacerhein in guinea pigs with osteoarthritis. Rev Prat Ed Fr, 1996, 46: S35-S39.; Fidelix TSA, Soares BGDO, Trevisani VF M. Diacerein for osteoarthritis. The Cochrane Database of Systematic Reviews, 2006.; Dougades M, Nguen M, Berdah L et al. Evaluation of the structure-modifying effects of Diacerhein in hip osteoarthritis. ECHODIAN, a three-year-placebo-controlled trial. Arthr Rheum, 2001, 44(11): 2539-47.; Носков С.М., Красивина И.Г., Широкова К.Ю. и др. Диацереин в терапии больных остеортрозом и ожирением. Тезисы VII Всероссийской конференции «Ревматология в реальной клинической практике». 2012, 37.; Леушина Е.А., Симонова О.В. Клиническая эффективность диацереина при остеоартрозе суставов кистей. Тезизы VII Всероссийской конференции «Ревматология в реальной клинической практике». 2012, 109.; https://www.med-sovet.pro/jour/article/view/1666

الاتاحة: https://www.med-sovet.pro/jour/article/view/1666
https://doi.org/10.21518/2079-701X-2017-0-84-89

المؤلفون: L. I. Alekseeva, N. G. Kashevarova, E. A. Taskina, E. P. Sharapova, S. G. Anikin, T. A. Korotkova, E. A. Strebkova, Л. И. Алексеева, Н. Г. Кашеварова, Е. А. Таскина, Е. П. Шарапова, С. Г. Аникин, Т. А. Короткова, Е. А. Стребкова

المصدر: Modern Rheumatology Journal; Том 11, № 3 (2017); 50-57 ; Современная ревматология; Том 11, № 3 (2017); 50-57 ; 2310-158X ; 1996-7012 ; 10.14412/1996-7012-2017-3

مصطلحات موضوعية: диацереин, treatment, diacerein, лечение

وصف الملف: application/pdf

Relation: https://mrj.ima-press.net/mrj/article/view/774/743; Qvist P, Bay-Jensen AC, Christiansen C, et al. The disease modifying osteoarthritis drug (DMOAD): Is it in the horizon? Pharmacol Res. 2008 Jul;58(1):1-7. doi:10.1016/j.phrs.2008.06.001. Epub 2008 Jun 8.; Bruyere O, Cooper C, Pelletier JP, et al. An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: A report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Semin Arthritis Rheum. 2014 Dec;44(3):253-63. doi:10.1016/j.semarthrit.2014.05.014. Epub 2014 May 14.; Martel-Pelletier J, Pelletier JP. Effects of diacerein at the molecular level in the osteoarthritis disease process. Ther Adv Musculoskelet Dis. 2010 Apr;2(2):95-104. doi:10.1177/1759720X09359104.; Martin G, Bogdanowicz P, Domagala F, et al. Rhein inhibits IL-1b – induced activation of MEK/ERK pathway and DNA binding of NF-kappa B and AP-1 in chondrocytes cultured in hypoxia: potential mechanism for its disease-modifying effect in osteoarthritis. Inflammation. 2003 Aug;27(4):233-46.; Алексеева ЛИ, Кашеварова НГ. Диацереин при лечении остеоартрита. Медицинский Совет. 2016;(8):86-91. [Alekseeva LI, Kashevarova NG. Diacerein in the treatment of osteoarthritis. Meditsinskii Sovet. 2016; (8):86-91. (In Russ.)]. doi:10.21518/2079-701X-2016-8-86-91; Pelletier JP, Lajeunesse D, Reboul P, et al. Diacerein reduces the excess synthesis of bone emodeling factors by human osteoblast cells from osteoarthritic subchondral bone. J Rheumatol. 2001 Apr;28(4):814-24.; Rintelen B, Neumann K, Leeb BF. A meta-analysis of controlled clinical studies with diacerein in the treatment of osteoarthritis. Arch Intern Med. 2006 Sep 25;166(17): 1899-906.; Fidelix TS, Soares BG, Trevisani VF. Diacerein for osteoarthritis. Cochrane Database Syst Rev. 2006 Jan25;(1):CD005117.; Bartels EM, Bliddal H, Schondorff PK, et al. Symptomatic efficacy and safety of diacerein in the treatment of osteoarthritis: a meta-analysis of randomized placebo-controlled trials. Osteoarthritis Cartilage. 2010 Mar;18(3):289-96. doi:10.1016/j.joca.2009.10.006. Epub 2009 Oct 14.; Удовика МИ. Диацереин как препарат выбора в терапии остеоартроза коленных суставов с вторичным рецидивирущим синовитом. Научно-практическая ревматология. 2015;(53)6:614-8. [Udovika MI. Diacerein as the drug of choice in the therapy of knee osteoarthritis with secondary recurrent synovitis. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2015;(53)6:614-8. (In Russ.)]. doi:10.14412/1995-4484-2015-614-618; Заиграева НК. Оценка эффективности препарата Артрокер при остеоартрозе коленных суставов. Современная ревматология. 2013;7(4):23-5. [Zaigraeva NK. Evaluation of the efficacy of Arthrocare for knee osteoarthrosis. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2013;7(4):23-5. (In Russ.)]. doi:10.14412/1996-7012-2013-2434; Dougados M, Nguen M, Berdah L, et al. Evaluation of the structure-modifying effects of Diacerhein in hip osteoarthritis. ECHODIAN, a three-year-placebo-controlled trial. Arthritis Rheum. 2001 Nov; 44(11):2539-47.; Fidelix TS, Macedo CR, Maxwell LJ, Fernandes Moca Trevisani V. Diacerein for osteoarthritis. Cochrane Database Syst Rev. 2014 Feb 10;(2):CD005117. doi:10.1002/14651858.CD005117.pub3.; Балабанова РМ. Применение диацереина для лечения остеоартроза крупных суставов (обзор литературы и собственный опыт). Современная ревматология. 2015;9(3):30–2. [Balabanova RM. Use of diacerein for the treatment of large joint osteoarthritis (A review of literature and the author’s own experience). Sovremennaya revmatologiya = Modern Rheumatology Journal. 2015;9(3):30–2. (In Russ.)]. doi:10.14412/1996-7012-2015-3-30-32; Pavelka K, Bruyere O, Cooper C, et al. Diacerein: Benefits, Risks and Place in the Management of Osteoarthritis. An Opinion- Based Report from the ESCEO. Drugs Aging. 2016 Feb;33(2):75-85. doi:10.1007/s40266-016-0347-4.; Носков СМ, Красивина ИГ, Широкова КЮ и др. Диацереин в терапии больных остеоартрозом и ожирением. Тезисы VII Всероссийской конференции «Ревматология в реальной клинической практике». 2012. 37 c. [Noskov SM, Krasivina IG, Shirokova KYu, et al. Diacerein therapy in patients with osteoarthrosis and obesity. Abstracts of the VII all- Russian conference «Rheumatology in clinical practice». 2012. 37 p.]; Шарапова ЕП, Кашеварова НГ, Зайцева ЕМ и др. Оценка эффективности и безопасности диацереина у пациентов с остеоартрозом тазобедренных суставов. Медицинский совет. 2017;(1s):84-9. [Sharapova EP, Kashevarova NG, Zaitseva EM, et al. Evaluation of the efficacy and safety of diacerein in patients with osteoarthritis of the hip joints. Meditsinskii sovet. 2017;(1s):84-9. (In Russ.)].; Леушина ЕА, Симонова ОВ. Клиническая эффективность диацереина при остеоартрозе суставов кистей. Лечащий врач. 2014;(10):90-2. [Leushina EA, Simonova OV. Clinical efficacy of diacerein in osteoarthritis joints of the hands. Lechashchii vrach. 2014;(10):90-2. (In Russ.)].; Лила АМ, Мартынова ЛВ, Лила ВА. Диацереин в терапии остеоартрита коленных суставов: результаты сравнительного исследования. Русский медицинский журнал. 2016;(2):70-7. [Lila AM, Martynova LV, Lila VA. Diacerein in the treatment of osteoarthritis of the knee: results of a comparative study. Russkii meditsinskii zhurnal. 2016;(2):70-7. (In Russ.)].; Pavelka K, Trc T, Karpas K, et al. The efficacy and safety of Diacerhein in the treatment of painful osteoarthritis of the knee: a randomized, multicentre, double-blind, placebo- controlled study with primery end points at two months after the end of a three month treatment period. Arthritis Rheum. 2007 Dec;56(12):4055-64.; Assessment report for diacerein containing medicinal products. 28 August 2014 EMA/527347/2014. Available from http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Diacerein/ European_Commission_final_decision/WC500173144.pdf; Каратеев АЕ, Алексеева ЛИ. Оценка переносимости диацереина в реальной клинической практике. Результаты исследования РОКАДА (Ретроспективная Оценка Клинических Аспектов применения Диафлекса при остеоАртрозе). Научно- практическая ревматология. 2015;53(2):169–74. [Karateev AE, Alekseeva LI. Estimation of Diacerein tolerability in real clinical practice: results of the racada (retrospective assessment of clinical aspects of using Diaflex in osteoarthritis). Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2015;53(2):169–74. (In Russ.)]. doi:10.14412/1995- 4484-2015-169-174; Pelletier JP, Yaron M, Haraoui B, et al. Efficacy and safety of diacerein in osteoarthritis of the knee: a double-blind, placebo-controlled trial. The Diacerein Study Group. Arthritis Rheum. 2000 Oct;43(10): 2339-48.; https://mrj.ima-press.net/mrj/article/view/774

الاتاحة: https://mrj.ima-press.net/mrj/article/view/774
https://doi.org/10.14412/1996-7012-2017-3-50-57

المؤلفون: E. V. Chetina, N. G. Kashevarova, E. P. Sharapova, Е. В. Четина, Н. Г. Кашеварова, Е. П. Шарапова

المصدر: Rheumatology Science and Practice; Vol 54, No 5 (2016); 590-597 ; Научно-практическая ревматология; Vol 54, No 5 (2016); 590-597 ; 1995-4492 ; 1995-4484 ; 10.14412/rsp20165

مصطلحات موضوعية: регуляция путей метаболизма, osteoarthritis, articular cartilage, peripheral blood, regulation of metabolic pathways, суставной хрящ, периферическая кровь

وصف الملف: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/2307/1511; Poole AR, Guilak F, Abramson SB. Etiopathogenesis of osteoarthritis. In: Moskowitz RW, Altman RD, Hochberg MC, et al., editors. Osteoarthritis: Diagnosis and Medical/Surgical Management. 4th ed. Lippincott, PA: Williams &Wilkins; 2007. P. 27-9.; Tchetina EV. Developmental mechanisms in articular cartilage degradation in osteoarthritis. Arthritis. 2011;2011:683970. doi:10.1155/2011/683970. Epub 2010 Dec 29.; Tchetina EV, Webb G, Poole AR. Increased type II collagen degradation and very early focal cartilage degeneration is associated with upregulation of chondrocyte differentiation related genes in early human articular cartilage lesions. J Rheumatol. 2005 May;32(5):876-86.; Tchetina EV, Kobayashi M, Yasuda T, et al. Chondrocyte hypertrophy can be induced by a cryptic sequence of type II collagen and is accompanied by the induction of MMP-13 and collagenase activity: implications for development and arthritis. Matrix Biology. 2007 May;26(4):247-58. doi:10.1016/j.mat-bio.2007.01.006. Epub 2007 Jan 19.; Tchetina EV, Antoniou J, Tanzer M, et al. Transforming growth factor-beta2 suppresses collagen cleavage in cultured human osteoarthritic cartilage, reduces expression of genes associated with chondrocyte hypertrophy and degradation, and increases prostaglandin E(2) production. Am J Pathol. 2006 Jan;168(1):131-40. doi:10.2353/ajpath.2006.050369; Glasson SS. In vivo osteoarthritis target validation utilizing genetically-modified mice. Curr Drug Targets. 2007 Feb;8(2):367-76. doi:10.2174/138945007779940061; Little CB, Fosang AJ. Is cartilage matrix breakdown an appropriate therapeutic target in osteoarthritis — insights from studies of aggrecan and collagen proteolysis? Curr Drug Targets. 2010 May;11(5):561-75. doi:10.2174/138945010791011956; Botter SM, Glasson SS, Hopkins B, et al. ADAMTS5-/micehave less subchondral bone changes after induction of osteoarthri-tis through surgical instability: implications for a link between cartilage and subchondral bone changes. Osteoarthr Cartilage. 2009 May;17(5):636-45. doi:10.1016/j.joca.2008.09.018. Epub 2008 Oct 17.; Bondeson J. Are we moving in the right direction with osteoarthritis drug discovery? Expert Opin Ther Targets. 2011 Dec;15(12):1355-68. doi:10.1517/14728222.2011.636740. Epub 2011 Nov 16.; Chevalier X, Mugnier B, Bouvenot G. Targeted anti-cytokine therapies for osteoarthritis. Bull Acad Natl Med. 2006 Oct;190(7):1411-20.; Gonzalo-Gil E, Criado G, Santiago B, et al. Transforming growth factor (TGF)-β signalling is increased in rheumatoid synovium but TGF-β blockade does not modify experimental arthritis. Clin Exp Immunol. 2013 Nov;174(2):245-55. doi:10.1111/cei.12179; Schroeppel JP, Crist JD, Anderson HC, Wang J. Molecular regulation of articular chondrocyte function and its significance in osteoarthritis. Histol Histopathol. 2011 Mar;26(3):377-94.; Rousseau JC, Delmas PD. Biological markers in osteoarthritis. Nat Clin Pract Rheumatol. 2007 Jun;3(6):346-56. doi:10.1038/ncprheum0508; Wu L, Huang X, Li L, et al. Insights on biology and pathology of HIF-1α/-2α, TGFβ/BMP, Wnt/β-catenin, and NF-κB pathways in osteoarthritis. Curr Pharm Design. 2012;18(22):3293-312. doi:10.2174/1381612811209023293; Scanzello CR, Plaas A, Crow MK. Innate immune system activation in osteoarthritis: is osteoarthritis a chronic wound? Curr Opin Rheumatol. 2008 Sept;20(5):565-72. doi:10.1097/BOR.0b013e32830aba34; Marcu KB, Otero M, Olivotto E, et al. NF-kappaB signaling: multiple angles to target OA. Curr Drug Targets. 2010 May;11(5):599-613. doi:10.2174/138945010791011938; Valdes AM, Spector TD. The clinical relevance of genetic susceptibility to osteoarthritis. Best Pract Res Clin Rheumatol. 2010 Feb;24(1):3-14. doi:10.1016/j.berh.2009.08.005; Dreier R. Hypertrophic differentiation of chondrocytes in osteoarthritis: the developmental aspect of degenerative joint disorders. Arthritis Res Ther. 2010;12(5):216. doi:10.1186/ar3117. Epub 2010 Sep 16.; Prasadam I, van Gennip S, Friis T, et al. ERK-1/2 and p38 in the regulation of hypertrophic changes of normal articular cartilage chondrocytes induced by osteoarthritic subchondral osteoblasts. Arthritis Rheum. 2010 May;62(5):1349-60. doi:10.1002/art.27397; Li TF, Gao L, Sheu TJ, et al. Aberrant hypertrophy in Smad3deficient murine chondrocytes is rescued by restoring transforming growth factor beta-activated kinase 1/activating transcription factor 2 signaling: a potential clinical implication for osteoarthritis. Arthritis Rheum. 2010 Aug;62(8):2359-69. doi:10.1002/art.27537; Berenbaum F. Signaling transduction: target in osteoarthritis. Curr Opin Rheumatol. 2004 Sep;16(5):616-22. doi:10.1097/01.bor.0000133663.37352.4a; Blom AB, van Lent PL, van der Kraan PM, van den Berg WB. To seek shelter from the WNT in osteoarthritis? WNT-signaling as a target for osteoarthritis therapy. Curr Drug Targets. 2010 May;11(5):620-9. doi:10.2174/138945010791011901; Walker WA, Blackburn G. Symposium introduction: nutrition and gene regulation. J Nutr. 2004 Sep;134(9):2434S-6S.; Marshall S. Role of insulin, adipocyte hormones, and nutrientsensing pathways in regulating fuel metabolism and energy homeostasis: a nutritional perspective of diabetes, obesity, and cancer. Sci STKE. 2006 Aug 1;2006(346):re7. doi:10.1126/stke.3462006re7; Kimball SR, Jefferson LS. Molecular mechanisms through which amino acids mediate signaling through the mammalian target of rapamycin. Curr Opin Clin Nutr Metab Care. 2004 Jan;7(1):39-44. doi:10.1097/00075197-200401000-00008; Maloney CA, Rees WD. Gene-nutrient interactions during fetal development. Reproduction. 2005 Oct;130(4):401-10. doi:10.1530/rep.1.00523; Laplante M, Sabatini DM. mTOR signaling at a glance. J Cell Sci. 2009 Oct 15;122(Pt 20):3589-94. doi:10.1242/jcs.051011; Altomare DA, Khaled AR. Homeostasis and the importance for a balance between AKT/mTOR activity and intracellular signaling. Curr Med Chem. 2012;19(22):3748-62. doi:10.2174/092986712801661130; Martin TD, Chen X-W, Kaplan REW, et al. Ral and Rheb GTPase activating proteins integrate mTOR and GTPase signaling in aging, autophagy, and tumor cell invasion. Mol Cell. 2014 Jan 22;53(2):209-20. doi:10.1016/j.molcel.2013.12.004. Epub 2014 Jan 2.; Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol. 2011 Jan;12(1):21-35. doi:10.1038/nrm3025. Epub 2010 Dec 15.; Wang RH, Kim HS, Xiao C, et al. Hepatic Sirt1 deficiency in mice impairs mTorc2/Akt signaling and results in hyperglycemia, oxidative damage, and insulin resistance. J Clin Invest. 2011 Nov;121(11):4477-90. doi:10.1172/JCI46243. Epub 2011 Oct 3.; Bohensky J, Leshinsky S, Srinivas V, Shapiro IM. Chondrocyte autophagy is stimulated by HIF-1 dependent AMPK activation and mTOR suppression. Pediatr Nephrol. 2010 Apr;25(4):633-42. doi:10.1007/s00467-009-1310-y. Epub 2009 Oct 15.; Kim MS, Wu KY, Auyeung V, et al. Leucine restriction inhibits chondrocyte proliferation and differentiation through mechanisms both dependent and independent of mTOR signaling. Am J Physiol Endocrinol Metab. 2009 Jun; 296(6):E1374-82. doi:10.1152/ajpendo.91018.2008. Epub 2009 Apr 28.; Sanchez CP, He Y-Z. Bone growth during rapamycin therapy in young rats. BMC Pediatrics. 2009 Jan 13;9:3. doi:10.1186/1471-2431-9-3; Rokutanda S, Fujita T, Kanatani N, et al. Akt regulates skeletal development through GSK3, mTOR, and FoxOs. Dev Biol. 2009 Apr 1;328(1):78-93. doi:10.1016/j.ydbio.2009.01.009. Epub 2009 Jan 14.; Lai LP, Lilley BN, Sanes JR, McMahon AP. Lkb1/Stk11 regulation of mTOR signaling controls the transition of chondrocyte fates and suppresses skeletal tumor formation. Proc Natl Acad Sci USA. 2013 Nov 26;110(48):19450-5. doi:10.1073/pnas.1309001110. Epub 2013 Nov 11.; Wei Y, Sinha S, Levine B. Dual role of JNK1-mediated phosphorylation of Bcl-2 in autophagy and apoptosis regulation. Autophagy. 2008 Oct;4(7):949-51. doi:10.4161/auto.6788. Epub 2008 Oct 14.; Cejka D, Hayer S, Niederreiter B, et al. Mammalian target of rapamycin signaling is crucial for joint destruction in experimental arthritis and is activated in osteoclasts from patients with rheumatoid arthritis. Arthritis Rheum. 2010 Aug;62(8):2294-302. doi:10.1002/art.27504; Tchetina EV, Poole AR, Zaitseva EM, et al. Differences in Mammalian target of rapamycin gene expression in the peripheral blood and articular cartilages of osteoarthritic patients and disease activity. Arthritis. 2013;2013:461486. doi:10.1155/2013/461486. Epub 2013 Jun 25.; Lotz MK, Carames B. Autophagy and cartilage homeostasis mechanisms in joint health, aging and OA. Nat Rev Rheumatol. 2011 Aug2;7(10):579-87. doi:10.1038/nrrheum.2011.109; Srinivas V, Bohensky J, Zahm AM, Shapiro IM. Autophagy in mineralizing tissues: microenvironmental perspectives. Cell Cycle. 2009 Feb 1;8(3):391-3. doi:10.4161/cc.8.3.7545; Srinivas V, Bohensky J, Shapiro IM. Autophagy: a new phase in the maturation of growth plate chondrocytes is regulated by HIF, mTOR and AMP kinase. Cells Tissues Organs. 2009;189(1-4):88- 92. doi:10.1159/000151428. Epub 2009 Feb 4.; Sasaki H, Takayama K, Matsushita T, et al. Autophagy modulates osteoarthritis-related gene expression in human chondrocytes. Arthritis Rheum. 2012 Jun;64(6):1920-8. doi:10.1002/art.34323. Epub 2011 Dec 6.; Raught B, Gingras AC, Sonenberg N. The target of rapamycin (TOR) proteins. Proc Natl Acad Sci USA. 2001 Jun 19;98(13):7037-44; Zhang M, Zhang J, Lu L, et al. Enhancement of chondrocyte autophagy is an early response in the degenerative cartilage of the temporomandibular joint to biomechanical dental stimulation. Apoptosis. 2013 Apr;18(4):423-34. doi:10.1007/s10495-013-0811-0; Shapiro IM, Adams CS, Freeman T, Srinivas V. Fate of the hypertrophic chondrocyte: microenvironmental perspectives on apoptosis and survival in the epiphyseal growth plate. Birth Defects Res C Embryo Today. 2005 Dec;75(4):330-9. doi:10.1002/bdrc.20057; Srinivas V, Shapiro IM. Chondrocytes embedded in the epiphyseal growth plates of long bones undergo autophagy prior to the induction of osteogenesis. Autophagy. 2006 Jul-Sep;2(3):215-6. doi:10.4161/auto.2649. Epub 2006 Jul 6.; Almonte-Becerril M, Navarro-Garcia F, Gonzalez-Robles A, et al. Cell death of chondrocytes is a combination between apoptosis and autophagy during the pathogenesis of osteoarthritis within an experimental model. Apoptosis. 2010 May;15(5):631-8. doi:10.1007/s10495-010-0458-z; Carames B, Taniguchi N, Otsuki S, et al. Autophagy is a protective mechanism in normal cartilage, and its aging-related loss is linked with cell death and osteoarthritis. Arthritis Rheum. 2010 Mar;62(3):791-801. doi:10.1002/art.27305; Carames B, Hasegawa A, Taniguchi N, et al. Autophagy activation by rapamycin reduces severity of experimental osteoarthritis. Ann Rheum Dis. 2012 Apr;71(4):575-81. doi:10.1136/annrheumdis-2011-200557. Epub 2011 Nov 14.; Phornphutkul C, Wu KY, Auyeung V, et al. mTOR signaling contributes to chondrocyte differentiation. Dev Dyn. 2008 Mar;237(3):702-12. doi:10.1002/dvdy.21464; Proud CG. Amino acids and mTOR signalling in anabolic function. Biochem Soc Trans. 2007 Nov;35(Pt 5):1187-90. doi:10.1042/BST0351187; Akhtar N, Miller MJ, Haqqi TM. Effect of a Herbal-Leucine mix on the IL-1β-induced cartilage degradation and inflammatory gene expression in human chondrocytes. BMC Complement Altern Med. 2011 Aug 19;11:66. doi:10.1186/1472-6882-11-66; Inoki K, Zhu T, Guan KL. TSC2 mediates cellular energy response to control cell growth and survival. Cell. 2003 Nov 26;115(5):577-90. doi:10.1016/S0092-8674(03)00929-2; Lee MN, Ha SH, Kim J, et al. Glycolytic flux signals to mTOR through glyceraldehyde-3-phosphate dehydrogenase-mediated regulation of Rheb. Mol Cell Biol. 2009 Jul;29(4):3991-4001. doi:10.1128/MCB.00165-09. Epub 2009 May 18.; Shikhman AR, Brinson DC, Lotz MK. Distinct pathways regulate facilitated glucose transport in human articular chondrocytes during anabolic and catabolic responses. Am J Physiol Endocrinol Metab. 2004 Jun;286(6):E980-5. doi:10.1152/ajpendo.00243.2003. Epub 2004 Jan 28.; Johnson K, Jung A, Murphy A, et al. Mitochondrial oxidative phosphorylation is a downstream regulator of nitric oxide effects on chondrocyte matrix synthesis and mineralization. Arthritis Rheum. 2000 Jul;43(7):1560-70. doi:10.1002/1529-0131(200007)43:73.0.CO;2-S; Martin JA, Martini A, Molinari A, et al. Mitochondrial electron transport and glycolysis are coupled in articular cartilage. Osteoarthr Cartilage. 2012 Apr;20(4):323-9. doi:10.1016/j.joca.2012.01.003. Epub 2012 Jan 16.; Baker MS, Bolis S, Lowther DA. Oxidation of articular cartilage glyceraldehyde-3-phosphate dehydrogenase (G3PDH) occurs in vivo during carrageenin-induced arthritis. Agents Actions. 1991 Mar;32(3-4):299-304. doi:10.1007/BF01980890; Nishida T, Kubota S, Aoyama E, Takigawa M. Impaired glycolytic metabolism causes chondrocyte hypertrophy-like changes via promotion of phospho-Smad1/5/8 translocation into nucleus. Osteoarthr Cartilage. 2013 May;21(5):700-9. doi:10.1016/j.joca.2013.01.013. Epub 2013 Feb 4.; Ruiz-Romero C, Carreira V, Rego I, et al. Proteomic analysis of human osteoarthritic chondrocytes reveals protein changes in stress and glycolysis. Proteomics. 2008 Feb;8(3):495-507. doi:10.1002/pmic.200700249; Jiang L, Li L, Geng C, et al. Monosodium iodoacetate induces apoptosis via the mitochondrial pathway involving ROS production and caspase activation in rat chondrocytes in vitro. J Orthop Res. 2013 Mar;31(3):364-9. doi:10.1002/jor.22250. Epub 2012 Nov 1.; Peansukmanee S, Vaughan-Thomas A, Carter SD, et al. Effects of hypoxia on glucose transport in primary equine chondrocytes in vitro and evidence of reduced GLUT1 gene expression in pathologic cartilage in vivo. J Orthop Res. 2009 Apr;27(4):529-35. doi:10.1002/jor.20772; Starkman BG, Cravero JD, Delcarlo M, Loeser RF. IGF-I stimulation of proteoglycan synthesis by chondrocytes requires activation of the PI 3-kinase pathway but not ERK MAPK. Biochem J. 2005 Aug 1;389(Pt 3):723-9. doi:10.1042/BJ20041636; Qureshi HY, Ahmad R, Sylvester J, Zafarullah M. Requirement of phosphatidylinositol 3-kinase/Akt signaling pathway for regulation of tissue inhibitor of metalloproteinases-3 gene expression by TGF-beta in human chondrocytes. Cell Signal. 2007 Aug;19(8):1643-51. doi:10.1016/j.cellsig.2007.02.007. Epub 2007 Feb 22.; Kahn BB, Alquier T, Carling D, Hardie DG. AMP-activated protein kinase: Ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab. 2005 Jan;1(1):15-25. doi:10.1016/j.cmet.2004.12.003; Gwinn DM, Shackelford DB, Egan DF, et al. AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell. 2008 Apr 25;30(2):214-26. doi:10.1016/j.molcel.2008.03.003; Terkeltaub R, Yang B, Lotz M, Liu-Bryan R. Chondrocyte AMPactivated protein kinase activity suppresses matrix degradation responses to proinflammatory cytokines interleukin-1β and tumor necrosis factor α. Arthritis Rheum. 2011 Jul;63(7):1928-37. doi:10.1002/art.30333; Petursson F, Husa M, June R, et al. Linked decreases in liver kinase B1 and AMP-activated protein kinase activity modulate matrix catabolic responses to biomechanical injury in chondrocytes. Arthritis Res Ther. 2013 Jul 25;15(4):R77. doi:10.1186/ar4254; Husa M, Petursson F, Lotz M, et al. C/EBP homologous protein drives pro-catabolic responses in chondrocytes. Arthritis Res Ther. 2013 Dec 19;15(6):R218. doi:10.1186/ar4415; Sofer A, Lei K, Johannessen CM, Ellisen LW. Regulation of mTOR and cell growth in response to energy stress by REDD1. Mol Cell Biol. 2005 Jul;25(14):5834-45. doi:10.1128/MCB.25.14.5834-5845.2005; Seol JW, Lee HB, Lee YJ, et al. Hypoxic resistance to articular chondrocyte apoptosis – a possible mechanism of maintaining homeostasis of normal articular cartilage. FEBS J. 2009 Dec;276(24):7375-85. doi:10.1111/j.1742-4658.2009.07451.x; Fermor B, Christensen SE, Youn I, et al. Oxygen, nitric oxide and articular cartilage. Eur Cell Mater. 2007 Apr 11;13:56-65.; Fermor B, Gurumurthy A, Diekman BO. Hypoxia, RONS and energy metabolism in articular cartilage. Osteoarthr Cartilage. 2010 Sep;18(9):1167-73. doi:10.1016/j.joca.2010.06.004. Epub 2010 Jul 13.; Mobasheri A, Platt N, Thorpe C, Shakibaei M. Regulation of 2-deoxy-D-glucose transport, lactate metabolism, and MMP-2 secretion by the hypoxia mimetic cobalt chloride in articular chondrocytes. Ann N Y Acad Sci. 2006 Dec;1091:83-93. doi:10.1196/annals.1378.057; Semenza GL. Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1. Annu Rev Cell Dev Biol. 1999;15:551-; Pfander D, Gelse K. Hypoxia and osteoarthritis: how chondrocytes survive hypoxic environments. Curr Opin Rheumatol. 2007 Sep;19(5):457-62. doi:10.1097/BOR.0b013e3282ba5693; Pfander D, Cramer T, Swoboda B. Hypoxia and HIF-1alpha in osteoarthritis. Int Orthop. 2005 Feb;29(1):6-9. doi:10.1007/s00264-004-0618-2. Epub 2004 Dec 21.; Gelse K, Mü hle C, Knaup K, et al. Chondrogenic differentiation of growth factor-stimulated precursor cells in cartilage repair tissue is associated with increased HIF-1alpha activity. Osteoarthr Cartilage. 2008 Dec;16(12):1457-65. doi:10.1016/j.joca.2008.04.006. Epub 2008 Jun 3.; Windhaber RA, Wilkins RJ, Meredith D. Functional characterisation of glucose transport in bovine articular chondrocytes. Pflugers Arch. 2003 Aug;446(5):572-7. doi:10.1007/s00424-003-1080-5. Epub 2003 May 15.; Carames B, Kiosses WB, Akasaki Y, et al. Glucosamine activates autophagy in vitro and in vivo. Arthritis Rheum. 2013 Jul;65(7):1843-52. doi:10.1002/art.37977; Mobasheri A, Vannucci SJ, Bondy CA, et al. Glucose transport and metabolism in chondrocytes: a key to understanding chondrogenesis, skeletal development and cartilage degradation in osteoarthritis. Histol Histopathol. 2002 Oct;17(4):1239-67.; Nakatani S, Mano H, Im R, et al. Glucosamine regulates differentiation of a chondrogenic cell line, ATDC5. Biol Pharm Bull. 2007 Mar;30(3):433-8. doi:10.1248/bpb.30.433; Terry DE, Rees-Milton K, Pruss C, et al. Modulation of articular chondrocyte proliferation and anionic glycoconjugate synthesis by glucosamine (GlcN), N-acetyl GlcN (GlcNAc) GlcN sulfate salt (GlcN.S) and covalent glucosamine sulfates (GlcN-SO4). Osteoarthr Cartilage. 2007 Aug;15(8):946-56. doi:10.1016/j.joca.2007.02.010. Epub 2007 Apr 2.; Piperno M, Reboul P, Hellio Le Graverand MP, et al. Glucosamine sulfate modulates dysregulated activities of human osteoarthritic chondrocytes in vitro. Osteoarthr Cartilage. 2000 May;8(3):207-12. doi:10.1053/joca.1999.0291; Gouze JN, Gouze E, Popp MP, et al. Exogenous glucosamine globally protects chondrocytes from the arthritogenic effects of IL-1beta. Arthritis Res Ther. 2006;8:R173. doi:10.1186/ar2082; Igarashi M, Kaga I, Takamori Y, et al. Effects of glucosamine derivatives and uronic acids on the production of glycosaminoglycans by human synovial cells and chondrocytes. Int J Mol Med. 2011 Jun;27(6):821-7. doi:10.3892/ijmm.2011.662. Epub 2011 Mar 31.; Pavelka K, Gatterova J, Olejarova M, et al. Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study. Arch Intern Med. 2002 Oct 14;162(18):2113-23. doi:10.1001/archinte.162.18.2113; Petersen SG, Saxne T, Heinegard D, et al. Glucosamine but not ibuprofen alters cartilage turnover in osteoarthritis patients in response to physical training. Osteoarthr Cartilage. 2010 Jan;18(1):34-40. doi:10.1016/j.joca.2009.07.004. Epub 2009 Jul 15.; Ali AA, Lewis SM, Badgley HL, et al. Oral glucosamine increases expression of transforming growth factor β1 (TGFβ1) and connective tissue growth factor (CTGF) mRNA in rat cartilage and kidney: implications for human efficacy and toxicity. Arch Biochem Biophys. 2011 Jun 1;510(1):11-8. doi:10.1016/j.abb.2011.03.014. Epub 2011 Apr 3.; Durmus D, Alayli G, Aliyazicioglu Y, et al. Effects of glucosamine sulfate and exercise therapy on serum leptin levels in patients with knee osteoarthritis: preliminary results of randomized controlled clinical trial. Rheumatol Int. 2013 Mar;33(3):593-9. doi:10.1007/s00296-012-2401-9. Epub 2012 Apr 3.; Henrotin Y, Mobasheri A, Marty M. Is there any scientific evidence for the use of glucosamine in the management of human osteoarthritis? Arthritis Res Ther. 2012 Jan 30;14(1):201. doi:10.1186/ar3657; Sherman AL, Ojeda-Correal G, Mena J. Use of glucosamine and chondroitin in persons with osteoarthritis. PM R. 2012 May;4(5 Suppl):S110-6. doi:10.1016/j.pmrj.2012.02.021; Iannone F, Lapadula G. Obesity and inflammation – targets for OA therapy. Curr Drug Targets. 2010 May;11(5):586-98. doi:10.2174/138945010791011857; Villavilla A, Gomez R, Largo R, Herrero-Beaumont G. Lipid transport and metabolism in healthy and osteoarthritic cartilage. Int J Mol Sci. 2013 Oct 16;14(10):20793-808. doi:10.3390/ijms141020793; Tong KM, Chen CP, Huang KC, et al. Adiponectin increases MMP-3 expression in human chondrocytes through AdipoR1 signaling pathway. J Cell Biochem. 2011 May;112(5):1431-40. doi:10.1002/jcb.23059; Kang EH, Lee YJ, Kim TK, et al. Adiponectin is a potential catabolic mediator in osteoarthritis cartilage. Arthritis Res Ther. 2010;12(6):R231. doi:10.1186/ar3218. Epub 2010 Dec 31.; Tang CH, Chiu YC, Tan TW, et al. Adiponectin enhances IL-6 production in human synovial fibroblast via an AdipoR1 receptor, AMPK, p38, and NF-kappa B pathway. J Immunol. 2007 Oct 15;179(8):5483-92. doi:10.4049/jimmunol.179.8.5483; Gkretsi V, Simopoulou T, Tsezou A. Lipid metabolism and osteoarthritis: Lessons from atherosclerosis. Prog. Lipid Res. 2011 Apr;50(2):133-40. doi:10.1016/j.plipres.2010.11.001. Epub 2010 Nov 27.; Kosinska MK, Liebisch G, Lochnit G, et al. A lipidomic study of phospholipid classes and species in human synovial fluid. Arthritis Rheum. 2013 Sep;65(9):2323-33. doi:10.1002/art.38053; Tsezou A, Iliopoulos D, Malizos KN, Simopoulou T. Impaired expression of genes regulating cholesterol efflux in human osteoarthritic chondrocytes. J Orthop Res. 2010 Aug;28(8):1033-9. doi:10.1002/jor.21084; Bernstein P, Sticht C, Jacobi A, et al. Expression pattern differences between osteoarthritic chondrocytes and mesenchymal stem cells during chondrogenic differentiation. Osteoarthr Cartilage. 2010 Dec;18(12):1596-607. doi:10.1016/j.joca.2010.09.007. Epub 2010 Sep 29.; Gabay O, Sanchez, Salvat C, et al. A phytosterol with potential anti-osteoarthritic properties. Osteoarthr Cartilage. 2010 Jan;18(1):106-16. doi:10.1016/j.joca.2009.08.019. Epub 2009 Sep 15.; Huang MJ, Wang L, Jin DD, et al. Enhancement of the synthesis of n-3 PUFAs in fat-1 transgenic mice inhibits mTORC1 signalling and delays surgically induced osteoarthritis in comparison with wild-type mice. Ann Rheum Dis. 2014 Sep;73(9):1719-27. doi:10.1136/annrheumdis-2013-203231. Epub 2013 Jul 12.; Loeser RF. Aging and osteoarthritis. Curr Opin Rheumatol. 2011 Sep;23(5):492-6. doi:10.1097/BOR.0b013e3283494005; Grcevic D, Jajic Z, Kovacic N, et al. Peripheral blood expression profiles of bone morphogenetic proteins, tumor necrosis factorsuperfamily molecules, and transcription factor Runx2 could be used as markers of the form of arthritis, disease activity, and therapeutic responsiveness. J Rheumatol. 2010 Feb;37(2):246-56. doi:10.3899/jrheum.090167. Epub 2009 Dec 15.; Mahr S, Burmester GR, Hilke D, et al. Cis and Trans-acting gene regulation is associated with osteoarthritis. Am J Hum Genet. 2006 May;78(5):793-803. doi:10.1086/503849. Epub 2006 Mar 22.; Marshal KW, Zhang H, Yager TD, et al. Blood-based biomarkers for detecting mild osteoarthritis in the human knee. Osteoarthritis Cartilage. 2005 Oct13;(10):861-71. doi:10.1016/j.joca.2005.06.002; Attur M, Belitskaya-Levy I, Oh C, et al. Increased interleukin-1β gene expression in peripheral blood leukocytes is associated with increased pain and predicts risk for progression of symptomatic knee osteoarthritis. Arthritis Rheum. 2011 Jul;63(7):1908-17. doi:10.1002/art.30360; Melemedjian OK, Khoutorsky A, Sorge RE, et al. mTORC1 inhibition induces pain via IRS-1-dependent feedback activation of ERK. Pain. 2013 Jul;154(7):1080-91. doi:10.1016/j.pain.2013.03.021. Epub 2013 Mar 15.; Laragione T, Gulko PS. MTOR regulates the invasive properties of synovial fibroblasts in rheumatoid arthritis. Mol Med. 2010 Sept-Oct;16(9-10):352-8. doi:10.2119/molmed.2010.00049. Epub 2010 May 27.; https://rsp.mediar-press.net/rsp/article/view/2307

الاتاحة: https://rsp.mediar-press.net/rsp/article/view/2307
https://doi.org/10.14412/1995-4484-2016-590-597

المؤلفون: E. A. Strebkova, I. V. Solovyeva, E. P. Sharapova, A. M. Mkrtumyan, L. I. Alekseeva, E. L. Nasonov, Е. А. Стребкова, И. В. Соловьева, Е. П. Шарапова, А. М. Мкртумян, Л. И. Алексеева, Е. Л. Насонов

المصدر: Rheumatology Science and Practice; Vol 53, No 4 (2015); 391-396 ; Научно-практическая ревматология; Vol 53, No 4 (2015); 391-396 ; 1995-4492 ; 1995-4484 ; 10.14412/rsp20154

مصطلحات موضوعية: орлистат, obesity, orlistat, ожирение

وصف الملف: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/2110/1338; Yusuf E. Metabolic factors in osteoarthritis: obese people do not walk on their hands. Arthritis Res Ther. 2012 Jul 19;14(4):123. doi:10.1186/ar3894; Аметов АС, Доскина ЕВ. Ожирение и современные методы лечения: Лекция для врачей. Москва: РМАПО; 2011. С. 3 [Ametov AS, Doskina EV. Ozhirenie i sovremennye metody lecheniya: Lektsiya dlya vrachei [Obesity and modern methods of treatment: A lecture for doctors]. Moscow: RMAPO; 2011. P. 3].; Toivanen AT, Heliö vaara M, Impivaara O, et al. Obesity, physically demanding work and traumatic knee injury are major risk factors for knee osteoarthritis – a population-based study with a follow-up of 22 years. Rheumatology (Oxford). 2010 Feb;49(2):308–14. doi:10.1093/rheumatology/kep388; Lohmander LS, Gerhardsson de Verdier M, Rollof J, et al. Incidence of severe knee and hip osteoarthritis in relation to different measures of body mass: a population-based prospective cohort study. Ann Rheum Dis. 2009 Apr;68(4):490–6. doi:10.1136/ard.2008.089748; Felson DT, Lawrence RC, Dieppe PA, et al. Osteoarthritis: new insights. Part 1: The disease and its risk factors FREE. Ann Intern Med. 2000;133(8):635–46. doi:10.7326/0003-4819- 133-8-200010170-00016; Reijman M, Pols H, Bergink AP, et al. Body mass index associated with onset and progression of osteoarthritis of the knee but not of the hip: The Rotterdam Study. Ann Rheum Dis. 2007;66:158–62. doi:10.1136/ard.2006.053538; Cimmino MA, Scarpa R, Caporali R, et al. Body mass and osteoarthritic pain: results from a study in general practice. Clin Exp Rheumatol. 2013 Nov-Dec;31(6):843–9. Epub 2013 Oct 17.; Altman R, Alarcon G, Appelrouth D, et al. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hip. Arthritis Rheum. 1991;34:505–14. doi:10.1002/art.1780340502; Marks R. Obesity profiles with knee osteoarthritis: correlation with pain, disability, disease progression. Obesity (Silver Spring). 2007 Jul;15(7):1867–74. doi:10.1038/oby.2007.221; Tanamas SK, Wluka AE. Association of weight gain with incident knee pain, stiffness, and functional dificulties: A longitudinal study. Arthr Care Res. 2013 Jan;65(1):34–43. doi 10.1002/acr.21745; Zhang W, Nuki G, Moskowitz RW, et al. OARSI recommendations for the management of hip and knee osteoarthritis: part III: Changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthr Cartilage. 2010 Apr;18(4):476–99. doi:10.1016/j.joca.2010.01.013; National Institutes of Health, National Heart Lung and Blood Institute. Evaluation, and Treatment of Overweight and Obesity in Adults. Clinical Guidelines on the Identification, 1998. P. 98–483.; Riddle DL, Stratford PW. Body weight changes and corresponding changes in pain and function in persons with symptomatic knee osteoarthritis: A cohort study. Arthr Care Res. 2013 Jan;65(1):15–22. doi 10.1002/acr.21692; Messier SP, Mihalko SL, Legault C, et al. Effects of intensive diet and exercise on knee joint loads, inflammation, and clinical outcomes among overweight and obese adults with knee osteoarthritis: the IDEA randomized clinical trial. JAMA. 2013 Sep 25;310(12):1263–73. doi:10.1001/jama.2013.277669; Савельева ЛВ. Современная концепция лечения ожирения: клинические рекомендации для; практикующих врачей. Фарматека. 2007;(12):33–8 [Savel'eva LV. The modern concept of treatment of obesity: clinical guidelines for medical practitioners. Farmateka. 2007;(12):33–8 (In Russ.)].; Tsigosa C, Hainerb V, Basdevantc A, et al. Management of Obesity in Adults: European Clinical Practice Guidelines. Obesity Facts. 2008;1:106–16. doi:10.1159/000126822; Бондаренко ИЗ, Бутрова СА, Гончаров НП. Лечение морбидного ожирения. Национальные клинические рекомендации. Ожирение и метаболизм. 2011;3:75–83 [Bondarenko IZ, Butrova SA, Goncharov NP. Treatment of morbid obesity. National clinical guidelines. Ozhirenie i metabolizm. 2011;3:75–83] (In Russ.)].; Toplak H, Ziegler O, Keller U, et al. X-PERT: weight reduction with orlistat in obese subjects receiving a mildly or moderately reduced-energy diet. Early response to treatment predicts weight maintenance. Diabetes Obes Metab. 2005;7:699–708. doi:10.1111/j.1463-1326.2005.00483.x; Finer N, James WPT, Kopelman PG, et al. One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicenter study of orlistat, a gastrointestinal lipase inhibitor. Int J Obes Relat Metab Disord. 2000;24:306–13. doi:10.1038/sj.ijo.0801128; Kadam U, Jordan K, Croft P. Clinical comorbidity in patients with osteoarthritis: a case-control study of general practice consulters in England and Wales. Ann Rheum Dis. 2004 Apr; 63(4):408–14. doi:10.1136/ard.2003.007526; Wirth A. Reduction of body weight and co-morbidities by orlistat: The XXL-Primary Health Care Trial. Diabetes Obes Metab. 2005 Jan;7(1):21–7. doi:10.1111/j.1463- 1326.2004.00428.x; Torgerson JS, Hauptman J, Boldrin MN, Sjö strö mL. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004 Jan;27(1):155–61. doi:10.2337/diacare.27.1.155; Richette P, Poitou C, Garnero P, et al. Benefits of massive weight loss on symptoms, systemic inflammation and cartilage turnover in obese patients with knee osteoarthritis. Ann Rheum Dis. 2011 Jan;70(1):139–44. doi:10.1136/ard.2010.134015; Colbert CJ, Almagor O, Chmiel JS, et al. Excess body weight and four-year function outcomes: comparison of African Americans and whites in a prospective study of osteoarthritis. Arthritis Care Res (Hoboken). 2013 Jan;65(1):5–14. doi:10.1002/acr.21811; https://rsp.mediar-press.net/rsp/article/view/2110

الاتاحة: https://rsp.mediar-press.net/rsp/article/view/2110
https://doi.org/10.14412/1995-4484-2015-391-396

المؤلفون: Lyudmila Ivanovna Alekseeva, E P Sharapova, N G Kashevarova, S G Anikin, T A Korotkova, E M Zaitseva, Людмила Ивановна Алексеева, Е. П. Шарапова, Н. Г. Кашеварова, С. Г. Аникин, Т. А. Короткова, Е. М. Зайцева

المصدر: Modern Rheumatology Journal; Том 8, № 1 (2014); 73-76 ; Современная ревматология; Том 8, № 1 (2014); 73-76 ; 2310-158X ; 1996-7012 ; 10.14412/1996-7012-2014-1

مصطلحات موضوعية: нежелательные явления, pain syndrome, aceclofenac, clinical effectiveness, tolerability, adverse effects, болевой синдром, ацеклофенак, клиническая эффективность, переносимость

وصف الملف: application/pdf

Relation: https://mrj.ima-press.net/mrj/article/view/514/492; Галушко ЕА. Медико-социальная зна- чимость ревматических заболеваний. Ав- тореферат диссертации на соискание уче- ной степени доктора медицинских наук. Москва; 2011. [Galushko EA. Mediko-sot- sial'naya znachimost' revmaticheskikh zabole- vanii. Avtoreferat dissertatsii na soiskanie uchenoi stepeni doktora meditsinskikh nauk. Moscow; 2011.] Алексеев ВВ. Современные представле- ния и основные принципы терапии боли. Спецвыпуск Болевой синдром. Русский медицинский журнал. 2011;19:6–11. [Alekseev VV. Sovremennye predstavleniya i osnovnye printsipy terapii boli. Spetsvypusk Bolevoi sindrom. Russkii meditsinskii zhur- nal. 2011;19:6–11.] Голубев ВЛ, Данилов А.Б. Психологи- ческие установки пациента и пережива- ние боли. Спецвыпуск Болевой синдром. Русский медицинский журнал. ;18:2–5. [Golubev VL, Danilov A.B. Psikhologicheskie ustanovki patsienta i perezhivanie boli. Spetsvypusk Bolevoi sin- drom. Russkii meditsinskii zhurnal. ;18:2–5.] Sowers JR, White WB, Pitt B, et al. The effects of cyclooxygenase-2 inhibitors and nonsteroidal anty-inflammatory therapy on -hour blood pressure in patients with hypertension, osteoarthritis and type 2 dia- betes mellitus. Arch Intern Med. ;165(2):161–8. DOI: http://dx.doi.org/10.1001/archinte.165.2.161. Ray WA, Varas-Lorenzo C, Chung CP, et al. Circ Cardiovasc Qual Outcomes. May;2(3):155–63. DOI:10.1161/CIR- COUTCOMES.108.805689. Epub 2009 May 5. Рекомендации OARSI по лечению ос- теоартроза коленных и тазобедренных су- ставов. Часть III; 2010 г. [Rekomendatsii OARSI po lecheniyu osteoartroza kolennykh i tazobedrennykh sustavov. Сhast' III; 2010 g.] Ding С. Do NSDIDs affect the progres- sion of osteoarthritis? Inflammation. ;26(3):139–42. Dingle JT. The effect of nonsteroidal anti- inflammatory drugs on human articular carti- lage glycosaminoglycan synthesis. Osteoarthritis Cartilage. 1999;7(3):313–4. DOI: http://dx.doi.org/10.1053/joca.1998.0176. Mastbergen SC, Jansen NWD, Bijlsma JWJ, et al. Differential direct effects of cyclo-oxygenase-1/2 inhibition on proteo- glycan turnover of human osteoarthritis сarti- lage: an in vitro study. Arthritis Res Ther. ;8(1):R2. DOI: 1186/ar1846. Akimoto H, Yamazaki R, et al. A major metabolite og aceclofenac 4-hydroxyace- clofenac suppresses the interleukin-1 induced production of promatrix metalloprpteinases and relese of sulfated- glycosaminoglycans from rabbit articular chondrocytes. Eur J Pharmacol. 2000;401(3):429–36. DOI: http://dx.doi.org/10.1016/S0014- (00)00472-6. Blot L, Marselis A, Devogelaer J-P, et al. Effects of diclofenac, aceclofenac and meloxicam on the metabolism of proteogly- cans and hyaluronan in osteoarthritic human cartilage. Br J Pharmacol. ;131(7):1413–21. DOI: http://dx.doi.org/10.1038/sj.bjp.0703710. Batlle-Gualda E, Roman Ivorra J, Martin-Mola E, et al. Aceclofenac vs parac- etamol in the management of systematic osteoarthritis of the knee: a double blind 6 week randomized controlled trial. Osteoarthritis Cartilage. 2007;15(8):900–8. Epub 2007 Mar 26. DOI: http://dx.doi.org/10.1016/j.joca.2007.02.008. Korsanoff D, Frericck H, Bowdler J, et al. Aceclofenac is well-tolerated alternarive to naproxen in the treatment osteoarthritis. Clin Rheumatol. 1997;16(1):32–8. DOI: http://dx.doi.org/10.1007/BF02238760. Peris F, Bird H, Semi U, et al. Treatment compliance and safety of aceclofenac versus standard NSAIDs in patients with common arthritic disorders: a meta-analysis. Eur J Rheumatol Inflamm. 1996;(16):37–45. Huskisson E, Irani M, Murray F. A large prospective open-label, multicentre SAMM study, comparing the safety of aceclofenac with diclofenac in patients withrheumatic dis- ease. Eur J Rheumatol Inflamm. ;7(1):1–7. Zabala Gamarra M. Efficacy and tolera- bility of aceclofenac in a 3-month open trial in the treatment of gonarthrosis. Dolor Inflamation 1993;(1):3–7. Diaz C, Rodriguez A, Geli C, et al. Efficacy and tolerability of aceclofenac versus diclofenac in the treatment of knee osteoarthritis. A multicenter study. Eur J Rheumatol Inflamm. 1996;(16):17–22. Calin A, Murrey FE. Aceclofenac: side effects and safety. Eur J Rheumatol Inflamm. ;(16):13–6. Korsanoff D, Frerick H, Bowdler J, Montull E. Aceclofenac is well-tolerated alternative to naproxen in the treatment osteoarthritis. Clin Rheumatol. ;16(1):32–8. DOI: http://dx.doi.org/10.1007/BF02238760. Pereя Busquer M, Calero E, Rodriguez M, et al. Comparison of aceclofenac with piroxi- cam in the treatment of osteoarthritis. Clin Rheumatol. 1997;16(2):154–9. DOI: http://dx.doi.org/10.1007/BF02247844. Шарапова ЕП, Алексеева ЛИ, Таскина ЕА и др. Ацеклофенак в терапии остеоартроза. Лечащий врач. 2012;8:90–5. [Sharapova EP, Alekseeva LI, Taskina EA, et al. Atseklofenak v terapii osteoartroza. Lechashchii vrach. 2012;8:90–5.]; https://mrj.ima-press.net/mrj/article/view/514

الاتاحة: https://mrj.ima-press.net/mrj/article/view/514
https://doi.org/10.14412/1996-7012-2014-1-73-76

المؤلفون: Lyudmila Ivanovna Alekseeva, E P Sharapova, E A Taskina, N V Chichasova, G R Imametdinova, N A Shostak, N G Pravdyuk, L N Denisov, Людмила Ивановна Алексеева, Е. П. Шарапова, Наталья Владимировна Чичасова, Г. Р. Имаметдинова, Н. А. Шостак, Н. Г. Правдюк

المصدر: Rheumatology Science and Practice; Vol 51, No 5 (2013); 532-538 ; Научно-практическая ревматология; Vol 51, No 5 (2013); 532-538 ; 1995-4492 ; 1995-4484 ; 10.14412/1995-4484-2013-5

مصطلحات موضوعية: плацебо, double-blind randomized placebo-controlled trial, alflutop, placebo, слепое рандомизированное плацебоконтролируемое исследование, алфлутоп

وصف الملف: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/1340/1000; Эрдес ШФ, Фоломеева ОМ. Ревматические заболевания и инвалидность взрослого населения Российской Федерации. Научно-практическая ревматология. 2007;(4):4–10. [Erdes ShF, Folomeeva OM. Revmaticheskie zabolevaniya i invalidnost' vzroslogo naseleniya Rossiyskoy Federatsii. Nauchno-prakticheskaya revmatologiya. 2007;(4):4–10.] Галушко ЕА. Медико-социальная значимость ревматических заболеваний. Автореферат диссертации на соискание ученой степени доктора медицинских наук. Москва; 2011. [Galushko EA. Mediko-sotsial'naya znachimost' revmaticheskikh zabolevaniy. Avtoreferat dissertatsii na soiskanie uchenoy stepeni doktora meditsinskikh nauk. Moscow; 2011.] Алексеев ВВ. Современные представления и основные принципы терапии боли. Русский медицинский журнал. 2011;(19 специальный выпуск «Болевой синдром»):6–11. [Alekseev VV. Sovremennye predstavleniya i osnovnye printsipy terapii boli. Russkiy meditsinskiy zhurnal. 2011;(19 spetsial'nyy vypusk «Bolevoy sindrom»):6–11]. Зайцева ЕМ, Алексеева ЛИ, Смирнов АВ. Причины боли при остеоартрозе и факторы прогрессирования заболевания. Научно-практическая ревматология. 2011;(1):50–7. [Zaitseva EM, Alekseyeva LI, Smirnov AV. The causes of pain in osteoarthrosis and the factors of disease progression. Nauchno-prakticheskaya revmatologiya. 2011;(1):50–7.] Алексеева ЛИ. Современные подходы к лечению остеоартроза. Русский медицинский журнал. 2003;11(4):201–5. [Alekseeva LI. Sovremennye podkhody k lecheniyu osteoartroza. Russkiy meditsinskiy zhurnal. 2003;11(4):201–5.] Boureau F, Schneid H, Zeghari N et al. The IPSO study: ibuprofen, paracetamol study in osteoarthritis. A randomized comparative clinical study comparing the efficacy and safety of ibuprofen and paracetamol analgesic treatment of osteoarthritis of knee or hip. Ann Rheum Dis. 2004;63(9):1028–35. DOI:10.1136%2Fard.2003.011403. Zhang W, Jones A, Doherty M. Does paracetamol (acetaminophen) reduce pain of osteoarthritis? A meta-analysis of randomized controlled trials. Ann Rheum Dis. 2004;63(8):901–7. DOI:10.1136%2Fard.2003.018531. Epub 2004 Mar 5. Каратеев АЕ, Яхно НН, Лазебник ЛБ и др. Применение нестероидных противовоспалительных препаратов. Клинические рекомендации. Москва: ИМА-ПРЕСС; 2009. 168 с. [Karateev AE, Yakhno NN, Lazebnik LB i dr. Primenenie nesteroidnykh protivovospalitel'nykh preparatov. Klinicheskie rekomendatsii. Mосква: IMA-PRESS; 2009. 168 p.] Mankin HS, Brandt KD. Biochemistry and metabolism of cartilage in osteoarthritis. In: Moskowitz RW, Hawel DS, Goldberg VM et al., editors. Osteoarthritis Diagnosis and Management. Philadelphia: W.B. Saunders; 1992;109–54. Гроппа Л, Мынзату И, Карасава М и др. Эффективность алфлутопа у больных деформирующим артрозом. Клиническая ревматология. 1995;3:20–2. [Groppa L, Mynzatu I, Karasava M i dr. Effektivnost' alflutopa u bol'nykh deformiruyushchim artrozom. Klinicheskaya revmatologiya. 1995;3:20–2.] Лукина ГВ, Сигидин ЯА. Опыт применения препарата алфлутоп в лечении остеоартроза. Научно-практическая ревматология. 1996;4:40–3. [Lukina GV, Sigidin YaA. Opyt primeneniya preparata alflutop v lechenii osteoartroza. Nauchno-prakticheskaya revmatologiya. 1996;4:40–3.] Лукина ГВ, Сигидин ЯА. Хондропротективный препарат алфлутоп в лечении остеоартроза. Научно-практическая ревматология. 2001;2:51–3. [Lukina GV, Sigidin YA. Chondroprotective drug alflutop in the treatment of osteoarthritis. Nauchno-prakticheskaya revmatologiya. 2001;2:51–3.] Коршунов НИ, Марасаев ВВ, Баранова ЭЯ и др. Роль воспаления и оценка хондропротективного действия Алфлутопа у больных с остеоартрозом по данным магнитно-резонансной томографии коленного сустава. Русский медицинский журнал. 2003;11(2):13–20. [Korshunov NI, Marasaev VV, Baranova EYa i dr. Rol' vospaleniya i otsenka khondroprotektivnogo deystviya Alflutopa u bol'nykh s osteoartrozom po dannym magnitno-rezonansnoy tomografii kolennogo sustava. Russkiy meditsinskiy zhurnal. 2003;11(2):13–20.] Светлова МС, Игнатьева ВК. Применение алфлутопа в лечении больных остеоартрозом. Клиническая медицина. 2004;82(6):52–5. [Svetlova MS, Ignatyev VK. Use of alflutop in the treatment of patients with osteoarthrosis. Klinicheskaya meditsina. 2004;82(6):52–5.] Дроздов ВН, Коломеец ЕВ. Применение алфлутопа у больных остеоартрозом с гастропатией, развившейся на фоне лечения НПВП. Фарматека. 2005;20:125–8. [Drozdov VN, Kolomeets EV. Primenenie alflutopa u bol'nykh osteoartrozom s gastropatiey, razvivsheysya na fone lecheniya NPVP. Farmateka. 2005;20:125–8.]; https://rsp.mediar-press.net/rsp/article/view/1340

الاتاحة: https://rsp.mediar-press.net/rsp/article/view/1340
https://doi.org/10.14412/1995-4484-2013-1545

المؤلفون: E V Chetina, E A Bratygina, E M Zaitseva, E P Sharapova, L A Semenova, N A Demin, L I Alekseyeva, S I Glukhova, V V Kolomatsky, M A Makarov, A L Logunov, A A Roskidailo, S A Makarov, Е. М. Зайцева, Е. П. Шарапова, Л. А. Семенова, С. И. Глухова, В. В. Коломацкий, М. А. Макаров, А. Л. Логунов, А. А. Роскидайло, С. А. Макаров

المصدر: Rheumatology Science and Practice; Vol 50, No 1 (2012); 27-32 ; Научно-практическая ревматология; Vol 50, No 1 (2012); 27-32 ; 1995-4492 ; 1995-4484 ; 10.14412/1995-4484-2012-1

مصطلحات موضوعية: кровь, osteoarthrosis, gene expression, mTOR, blood, экспрессия генов

Relation: Четина Е.В. Механизмы эмбриогенеза при остеоартрозе: роль дифференцировки хондроцитов в резорбции суставного хряща. Науч-практич ревматол 2010;3:65-77. Buckwalter J.A., Saltzman C., Brown T. et al. The impact of osteoarthritis: implications for research. Clin Orthop 2004;427:S6-S15. Dean D.D., Azzo W., Martel-Pelletier J. et al. Evidence for metalloproteinase and metalloproteinase inhibitor imbalance in human osteoarthritic cartilage. J Clin Invest 1989;84:678-85. Muller B. Cytokine imbalance in non-immunological chronic disease. Cytokine 2002;18:334-9. Aigner T., Rose J., Martin J. et al. Aging theories of primary osteoarthritis: from epidemiology to molecular biology. Rejuvenation Res 2004;7:134-45. Lorenzo P., Bayliss M.T., Heinegard D. Altered patterns and synthesis of extracellular matrix macromolecules in early osteoarthritis. Matrix Biol 2004;23:381-91. Sharif M., Whitehouse A., Sharman P. et al. Increased apoptosis in human osteoarthritic cartilage corresponds to reduced cell density and expression of caspase 3. Arthr Rheum 2004;50:507-15. Четина Е.В., Пул А.Р. Способность фрагмента коллагена 2 типа индуцировать расщепление коллагена и гипертрофию суставных хондроцитов. Bестн. РАМН 2008;9:40-5. Tchetina E.V., Webb G., Poole A.R. Increased type II collagen degradation and very early focal cartilage degeneration is associated with upregulation of chondrocyte differentiation related genes in early human articular cartilage lesions. J Rheumatol 2005;32:876-86. Четина Е.В., Пул А.Р. Роль ростовых факторов в подавлении разрушения коллагена и дифференциации хондроцитов при остеоартрозе. Bестн РАМН 2008;5:15-21. Четина Е.В., ДиБатиста Д., Пул А.Р. Роль простагландина E2 в ингибировании разрушения коллагена суставного хряща больных остеоартрозом. Науч-практич ревматол 2009;3:18-23. Mahr S., Burmester G.-R., Hilke D. et al. Cis and Trans-acting gene regulation is associated with osteoarthritis. Am J Hum Genet 2006;78:793-803. Grcevic D., Jajic Z., Kovacic N. et al. Peripheral blood expression profiles of bone morphogenetic proteins, tumor necrosis factor-superfamily molecules, and transcription factor Runx2 could be used as markers of the form of arthritis, disease activity, and therapeutic responsiveness. J Rheumatol 2010;37:246-56. Sesselmann S., Söder S., Voigt R. et al. DNA methylation is not responsible for p21WAF1/CIP1 down-regulation in osteoarthritic chondrocytes. Osteoarthr Cartilage 2009;17:507-12. Fukuda K. Progress of research for osteoarthritis. Involvement of reactive oxygen species in the pathogenesis of osteoarthritis. Clin Calcium 2009;19:1602-6. Dai S.M., Shan Z.Z., Nakamura H. et al. Catabolic stress induces features of chondrocyte senescence through overexpression of caveolin 1: possible involvement of caveolin 1-induced down-regulation of articular chondrocytes in the pathogenesis of osteoarthritis. Arthr Rheum 2006;54:818-31. Zhou H.W., Lou S.Q., Zhang K. Recovery of function in osteoarthritic chondrocytes induced by p16INK4a-specific siRNA in vitro. Rheumatology (Oxford) 2004;43:555-68. Hay N., Sonnenberg N. Upstream and downstream of mTOR. Genes Dev 2004;18:1926-45. Raught B., Gingras A.C., Sonenberg N. The target of rapamycin (TOR) proteins. Proc Natl Аcad Sci USA 2005;98:7037-44. Lum J.J., DeBerardinis R.J., Thompson C.B. Autophagy in metazoans: cell survival in the land of plenty. Nat Rev Mol Cell Biol 2005;6:439-48. Roach H.I., Aigner T., Kouri J.B. Chondroptosis: a variant of apoptotic cell death in chondrocytes? Apoptosis 2004;9:265-77. Lu B., Capan E., Li C. Autophagy induction and autophagic cell death in effector T cells. Autophagy 2007;3:158-9. Wei Y., Sinha S., Levine B. Dual role of JNK1-mediated phosphorylation of Bcl-2 in autophagy and apoptosis regulation. Autophagy 2008;4:949-51. Patel V.A., Lee D.J., Longacre-Antoni A. et al. Apoptotic and necrotic cells as sentinels of local tissue stress and inflammation: Response pathways initiated in nearby viable cells. Autoimmunity 2009;42:317-21 Zhu M., Chen M., Zuscik M. et al. Inhibition of beta-catenin signaling in articular chondrocytes results in articular cartilage destruction. Arthr Rheum 2008;58:2053-64. Aigner T., Hemmel M., Neureiter D. et al. Apoptotic cell death is not a widespread phenomenon in normal aging and osteoarthritis human articular knee cartilage: a study of proliferation, programmed cell death (apoptosis), and viability of chondrocytes in normal and osteoarthritic human knee cartilage. Arthr Rheum 2001;44:1304-12. Goldring S.R., Goldring M.B. The role of cytokines in cartilage matrix degeneration in osteoarthritis. Clin Orthopaed 2004;427(Suppl.):S27-S36. Goldring S.R., Berenbaum F. The regulation of chondrocyte function by proinflammatory mediators: prostaglandins and nitric oxide. Clin Orthopaed 2004;427(Suppl.):S37-S46. Benito M.J., Veale D.J., FitzGerald O. et al. Synovial tissue inflammation in early and late osteoarthritis. Annals Rheum Dis 2005;64:1263-7. Fernandes J.C., Martel-Pelletier J., Pelletier J.P. The role of cytokines in osteoarthritis pathophysiology. Biorheology 2002;39:237-46. Лимфоциты - методы. Под. ред. Д. Клауса М., 1990. Batliwalla F.M., Baechler E.C., Xiao X. et al. Peripheral blood gene expression profiling in rheumatoid arthritis. Genes Immun 2005;6:388-97. Bonnet C.S., Walsh D.A. Osteoarthritis, angiogenesis and inflammation. Rheumatology 2005;44:7-16. Poole A.R. Cartilage in health and disease. In: Arthritis and allied conditions: A textbook of rheumatology. Ed. 15. Ed. by W. Koopman. Philadelphia: Lippincott, Williams, and Wilkins, 2005;223-69. Abou-Shousha S.A., Salah E., Wagby E. Study of P53 in peripheral blood and synovial mononuclear cells of rheumatoid arthritis and osteoarthritis patients and its relation to the degree of disease activity. Egypt J Immunol 2005;12:61-70. Sigal L.H., Johnston S.L., Phillips P.E. Cellular immune responses to cartilage components in rheumatoid arthritis and osteoarthritis: a review and report of a study. Clin Exp Rheumatol 1988;6:59-66. Бененсон Е.В., Тсай Е.Г., Табушалиева А.С. Иммунорегуляторные нарушения и пролиферативная активность Т- и В-лимфоцитов при остеоартрозе. Ревматология 1989;2:45-9. Conrozier T., Chappuis-Cellier C., Richard M. et al. Increased serum C-reactive protein levels by immunonephelometry in patients with rapidly destructive hip osteoarthritis. Rev Rhum Engl Ed 1998;65:759-65. Spector T.D., Hart D.J., Nandra D. et al. Low-level increases in serum C-reactive protein are present in early osteoarthritis of the knee and predict progressive disease. Arthr Rheum 1997;40:723-7.; https://rsp.mediar-press.net/rsp/article/view/638

الاتاحة: https://rsp.mediar-press.net/rsp/article/view/638
https://doi.org/10.14412/1995-4484-2012-500

المؤلفون: L N Denisov, J G Slesina, M S Petrova, O F Ryabitseva, I V Kudryavtseva, G S Arhangelskaya, I A Sborovskaya, L P Filimonova, M L Stanislav, E Y Panasyuk, E P Sharapova, Е. Ю. Панасюк, Е. П. Шарапова

المصدر: Rheumatology Science and Practice; Vol 45, No 3 (2007); 34-39 ; Научно-практическая ревматология; Vol 45, No 3 (2007); 34-39 ; 1995-4492 ; 1995-4484 ; 10.14412/1995-4484-2007-3

وصف الملف: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/823/515; Алексеева J1.И., Чичасова Н.В., Беневоленская Л.И.и соавт. Перспективы комбинированной хондропротективной терапии остеоартроза. Научно-практич. ревматол., 2004, 4, 77-79. Бадокин И.И. Пути оптимизации терапии остеоартроза. Русс, мед.журн., 2006, 14, 25, 18241829. Насонов Е.Л. Современные направления фармакотерапии остеоартроза. Consilium Medicum, 2004, 3, 9, 408-415. Насонов Е.Л., Каратеев А.Е. Применение нестероидных противовоспалительных препаратов. Клинические рекомендации. Русс. мед. журн., 2006, 14, 25,1769-1777. Цветкова Е.С., Иониченок Н.Г., Карусинов П.С.и соавт. Клинико-инструментальная оценка влияния фармакотерапии на течение остеоартроза коленных суставов. Научно-практич. ревматол., 2007, 1,69-75. Jordan К.М., Arden Н., Doherty М. et al, EULAR Recommendations 2003: an evidence based approach to the management of osteoarthritis: Report ofa task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann. Rheum.Dis., 2003, 1, 1-13. Leeb B.F.,Schweizer H., Montag K., Smolen J.S. Metabolism of chondroitin sulfate in the treatment of osteoarthritis. J.Rheumatol., 2000, 27, 205-211. Regisnter J.V., Deroisy R., Paul J.et al. Long-term effects of glucosamin sulfate in osteoarthritis progression,a randomized, placebo-controlled clinical trial. Lancet, 2001, 375, 251-256.; https://rsp.mediar-press.net/rsp/article/view/823

الاتاحة: https://rsp.mediar-press.net/rsp/article/view/823
https://doi.org/10.14412/1995-4484-2007-686